Synthesis of Phosphonopeptides and Alpha, Alpha-Dialkylated Amino Acid-Rich Peptides. by Rushing, Sheila Denise
Louisiana State University
LSU Digital Commons
LSU Historical Dissertations and Theses Graduate School
2001
Synthesis of Phosphonopeptides and Alpha, Alpha-
Dialkylated Amino Acid-Rich Peptides.
Sheila Denise Rushing
Louisiana State University and Agricultural & Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact
gradetd@lsu.edu.
Recommended Citation
Rushing, Sheila Denise, "Synthesis of Phosphonopeptides and Alpha, Alpha-Dialkylated Amino Acid-Rich Peptides." (2001). LSU
Historical Dissertations and Theses. 314.
https://digitalcommons.lsu.edu/gradschool_disstheses/314
INFORMATION TO USERS
This manuscript has been reproduced from the microfilm master. UMI films 
the text directly from the original or copy submitted. Thus, some thesis and 
dissertation copies are in typewriter face, while others may be from any type of 
computer printer.
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality illustrations 
and photographs, print bleedthrough, substandard margins, and improper 
alignment can adversely affect reproduction..
In the unlikely event that the author did not send UMI a complete manuscript 
and there are missing pages, these will be noted. Also, if unauthorized 
copyright material had to be removed, a note will indicate the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand comer and continuing 
from left to right in equal sections with small overlaps.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9” black and white 
photographic prints are available for any photographs or illustrations appearing 
in this copy for an additional charge. Contact UMI directly to order.
ProQuest Information and Learning 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 
800-521-0600
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
SYNTHESIS OF PHOSPHONOPEPTEDES AND ALPHA, 
ALPHA-DIALKYLATED AMINO ACID-RICH PEPTIDES
A Dissertation
Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy
in
The Department of Chemistry
by
Sheila Denise Rushing 
B.S., Tougaloo College, 1996 
May, 2001
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
UMI Number. 3016577
UMI’
UMI Microform 3016577 
Copyright 2001 by Bell & Howell Information and Learning Company. 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code.
Bell & Howell Information and Learning Company 
300 North Zeeb Road 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
This dissertation is dedicated to: 
my compassionate and supportive husband,
Judson 
It’s reaping time!!!
and to my parents (Mr. and Mrs. Rushing) and grandmother (Thelma Mobley) 
for all of your love, encouragement, and support.
ii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Acknowledgements
Hallelujah!!! I would first like to thank God for providing me with the strength, wisdom, 
and intense desire needed for successful completion of my formal educational training.
I give thanks and appreciation to my advisor, Dr. Robert P. Hammer, for his 
support, guidance, and expressive belief in my abilities as a scientist. Working in his 
bioorganic group was truly a rewarding experience-especially in terms of skills and 
knowledge gained and professional and personal growth.
An abundant of love and gratitude goes to my wonderful, supportive husband, Dr. 
Judson L. Haynes, HI. Thanks for countless encouraging words and actions and for very 
insightful and beneficial information you provided about the graduate school process.
I give special thanks and honor to my parents, Johnnie Mae and Clifton Rushing, 
for their innumerable prayers for me as well as their inspiring words of encouragement 
and never-ending faith in me. I also acknowledge my siblings-Sandra, Curtis, Clifton, 
Diane, Steven, Jeffrey, Johnny, and Jennifer-for their emotional and spiritual support. In 
addition, I give special acknowledgements to the Haynes family, particularly, Omita and 
Judson Haynes and Chiara Haynes, for their genuine concern and prayers for me during 
my tenure at LSU.
A significant amount of thanks is given to Martha Juban for help with peptide 
synthesis, Dr. Tracy McCarley for mass specs, Dr. Dale Treleavan and Dr. Frank Zhou 
for assistance with NMR techniques, Natha Booth for biological studies, Henry Hurtado 
and Luz Barona for assistance in drafting shop. I also greatly appreciate the contributions 
and support from members of Hammer’s group: Dr. Maria Fernandez, Dr. Hong Fan, 
Yanwen Fu, Christopher Wysong, Dr. Kristofer Moffett, Dr. Tod Miller, Hannah
iii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Farquar, Dr. Andrea Saurage, and Courtney Brown. In addition, I give thanks and 
appreciation to the faculty and staff of LSU.
Finally, I would like to thank all of my committee members, Dr. Robert P. 
Hammer, Dr. Mark McLaughlin, Dr. Robert Strongin, Dr. Isiah M. Warner, and Dr. 
Frederick Enright.
iv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table of Contents
Acknowledgements........................................................................................................iii
List of Tables................................................................................................................. vii
List of Figures................................................................................................................ ix
List of Schemes.............................................................................................................. xii
List of Abbreviations....................................................................................................xiv
Abstract.......................................................................................................................xviii
Chapter 1 Introduction............................................................................................... 1
1.1 A Brief Overview of Peptides and Peptide Analogs......................................... 1
1.2 Importance of Phosphonopeptides....................................................................3
1.3 Synthetic Strategies for Phosphonate Esters and Amide.................................. 6
1.4 Phosphorus (HI) Synthetic Approach............................................................... 8
1.5 Peptide Secondary Structure........................................................................... 12
1.6 Amphipathic a-helix.......................................................................................15
1.7 Significance of a,a-Dialkylated Amino Acids in Short Peptides.................... 18
1.8 Synthesis of Short, Helical Peptides...............................................................20
1.9 Circular Dichroism Spectroscopy...................................................................22
1.10 References..................................................................................................... 24
Chapter 2 Synthesis of Phosphonamides and Thiophosphonamides by
A One-pot Activation-Coupling-Oxidation Procedure......................... 30
2.1 Introduction..................................................................................................... 30
2.2 Results and Discussion.................................................................................... 31
2.2.1 Examination of Activation Reaction......................................................33
2.2.2 Coupling Step........................................................................................ 35
2.2.3 Role of Amine-Protecting Group...........................................................47
2.2.4 Use of Resin-bound PI13PCI2..................................................................53
2.2.5 Synthesis of Protected a-Amino-Alkyl-H-Phosphinate Esters.............. 55
2.3 Conclusions..................................................................................................... 58
2.4 Experimental Material..................................................................................... 59
2.4.1 Technical Information........................................................................... 59
2.4.2 General Procedure................................................................................. 59
2.4.3 Synthesis and Characterization of 1-Amino-l-CycIohexyl- 
methanephosphonous acid.....................................................................60
2.4.4 Synthesis and Characterization of Protected 1-Amino-l- 
Cyclohexylmethanephosphonous acids................................................. 61
v
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2.4.5 Synthesis and Characterization of Protected 1-Amino-l- 
Cyclohexylmethane-H-Phosphinate Esters..........................................63
2.4.6 Preparation of Oxazaphospholine 7 using PS-DIEA Resin.................65
2.4.7 Synthesis and Characterization of Complex Phosphonamide
and Thiophosphonamide Dipeptides....................................................65
2.4.8 Synthesis and Characterization of Thiophosphonamides, 
Phosphonamides, and Thiophosphonates............................................ 67
2.5 References.................................................................................................... 6 8
Chapter 3 Synthesis of a,ce-Dialkylated Amino Acid-Rich Peptides
with Antimicrobial Activity................................................................... 71
3.1 Introduction.................................................................................................. 71
3.2 Results and Discussion.................................................................................76
3.2.1 Peptide Design and Synthesis.............................................................. 76
3.2.2 Solvent Effects on 3io-/a-Helix Equilibrium....................................... 87
3.2.3 Bioactivity of Designed Peptides....................................................... 118
3.3 Conclusions................................................................................................ 125
3.4 Experimental...............................................................................................127






3.4.5 Amino Acid Analysis.........................................................................131
3.4.6 Circular Dichroism Measurements.....................................................131
3.4.7 Minimum Inhibitory Concentration Assays....................................... 132
3.4.8 Macrophage Assays........................................................................... 132
3.5 References...................................................................................................133
Chapter 4 Summary and Future Studies.............................................................. 136
Vita...............................................................................................................................142
vi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Tables
Table 2.1 Phosphonochloridite generation under various solvent
and base conditions....................................................................................... 35
Table 2.2 Synthesis of phosphonamides and thiophosphonamides...............................46
Table 3.1 Sequences of peptides 3.1-3.10.....................................................................77
Table 3.2 CD data and derived structural parameters for Ipi-9 at 25 °C....................... 89
Table 3.3 CD data and derived structural parameters for Ipiom-9 at 25 °C...................89
Table 3.4 CD data and derived structural parameters for Ipidab-9 at 25 °C.................. 90
Table 3.5 CD data and derived structural parameters for Ipi-10 at 5 °C........................ 90
Table 3.6 CD data and derived structural parameters for Ipi-10 at 25 °C..................... 91
Table 3.7 CD data and derived structural parameters for Ipi-9 in buffer
(pH = 7) at 30 to 70 °C.................................................................................. 97
Table 3.8 CD data and derived structural parameters for Ipiom-9 in buffer
(pH = 7) at 30 to 70°C................................................................................... 97
Table 3.9 CD data and derived structural parameters for Ipidab-9 in buffer
(pH = 7) at 30 to 70 °C.................................................................................. 98
Table 3.10 CD data and derived structural parameters for Ipidap-9 in buffer
(pH = 7) at 30 to 70 °C.................................................................................. 99
Table 3.11 CD data and derived structural parameters for Ipi-9 in 25 mM SDS
at 30 to 70 °C..............................................................................................104
Table 3.12 CD data and derived structural parameters for Ipiom-9 in
25 mM SDS at 30 to 70 °C......................................................................... 105
Table 3.13 CD data and derived structural parameters for AcIpiom-9 at 25 °C..........108
Table 3.14 CD data and derived structural parameters for AcIpidab-9 at 25 °C......... 108
Table 3.15 CD data and derived structural parameters for Aclpi-10 at 25 °C.............. 109
Table 3.16 CD data and derived structural parameters for AcIpi-9 at 25 °C...............109
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 3.17 CD data and derived structural parameters for AcIpidap-9 at 25 °C.......... 114
Table 3.18 CD data and derived structural parameters for AcIpi-9 at 25 °C............. 115
Table 3.19 CD data and derived structural parameters for AcIpiom-9 at 25 °C.......... 115
Table 3.20 Peptide antibacterial activity and percent helicity..................................... 123
Table 3.21 Direct peptide toxicity effects on murine peritoneal macrophages.............124
Table 3.22 Characterization of Peptides 3.1-3.10.........................................................128
viii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Figures
Figure 1.1 Classes of peptide analogs...........................................................................3
Figure 1.2 Phosphonopeptide enzyme inhibitors.......................................................... 4
Figure 1.3 Torsional angles of a peptide backbone....................................................... 12
Figure 1.4 Hydrogen bonding pattern of an a-helix and 3to-helix.................................14
Figure 1.5 Helical wheel diagram of an amphipathic a-helix........................................15
Figure 1.6 CD spectra of poly-L-lysine in the a-helix, P, and random
Conformation................................................................................................23
Figure 2.1 Comparative GC-MS study of activation step............................................. 34
Figure 2.2 3lP NMR spectra.......................................................................................... 37
Figure 2.3 3lP NMR spectra of HPLC-purified la - lb ..................................................38
Figure 2.4 3lP NMR spectra of HPLC-purified lc-d....................................................38
Figure 2.5 Analytical HPLC purity check of isolated la  and lb .................................. 39
Figure 2.6 Analytical HPLC purity check of isolated lc  and Id .................................. 40
Figure 2.7 Trans and Cis conformer of oxazaphospholine 7.........................................41
Figure 2.8 31P NMR spectra of thiophosphonamides 12-13 and phosphon-
amide 14 after isolation............................................................................... 44
Figure 2.9 31P NMR spectra of phosphonates 19-20 after isolation...............................44
Figure 2.10 3lP NMR of alternate procedure for preparation of Id ................................ 46
Figure 2.11 Generation of oxazaphospholine 7 via PS-DIEA resin................................47
Figure 2.12 Non-urethane amine-protecting groups....................................................... 48
Figure 2.13 3lP NMR spectra of one-pot procedure with Nbs-protected
H-phosphinate 21........................................................................................51
Figure 2.14 31P NMR spectra of activation and coupling step of one-pot
procedure with Dde-protected H-phosphinate 22........................................52
ix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 2.15 Generation of resin-bound PhsPC^.............................................................54
Figure 2.16 31P NMR spectra of one-pot procedure with resin-bound
PhjPClz..................................................................................................... 55
Figure 3.1 Backbone torsional angles of an Aib residue............................................... 72
Figure 3.2 Short, water-soluble 3to-helical peptides......................................................74
Figure 3.3 General chemical structure of peptides 3.1*3.10.......................................... 78
Figure 3.4 The a-and 3io-helical wheel diagrams and sequence of
Peptides 3.1- .3.8.......................................................................................... 79
Figure 3.5 The residues employed in synthesis of peptides 3.1*3.10.............................80
Figure 3.6 Semi-preparatory HPLC profile of crude containing peptide
3.1 before improved coupling method.......................................................... 83
Figure 3.7 Semi-preparatory HPLC profile of crude containing peptide
3.1 after employing improved coupling protocol..........................................83
Figure 3.8 Analytical HPLC purity check of isolated 3.1...............................................84
Figure 3.9 Analytical HPLC purity check of isolated 3.2..................  84
Figure 3.10 Analytical HPLC purity check of isolated 3.4...............................................85
Figure 3.11 Analytical HPLC purity check of isolated 3.6...............................................85
Figure 3.12 Analytical HPLC purity check of isolated 3.9...............................................8 6
Figure 3.13 Analytical HPLC purity check of isolated 3.10............................................8 6
Figure 3.14 CD spectra of Ipi-9, Ipiom-9, Ipidab-9, and Ipidap-9 in 25 mM SDS.........93
Figure 3.15 CD spectra of Ipi-9, Ipiom-9, Ipidab-9, and Ipidap-9 in neutral,
aqueous buffer at 25 °C............................................................................... 94
Figure 3.16 CD spectra of Ipi-9, Ipiom-9, Ipidab-9, and Ipidap-9 in
CH3CN-H2O (9:1) at 25 °C......................................................................... 95
Figure 3.17 CD spectra of Ipi-9, Ipiom-9, Ipidab-9, and Ipidap-9 in
CH3CN-TFE (9:1) at 25 °C..........................................................................96
x
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 3.18 CD spectra of Ipi-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C in
neutral, aqueous buffer............................................................................. 1 0 0
Figure 3.19 CD spectra of Ipiom-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C
in neutral, aqueous buffer.......................................................................... 10 1
Figure 3.20 CD spectra of Ipidab-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C
in neutral, aqueous buffer.......................................................................... 1 0 2
Figure 3.21 CD spectra of Ipidap-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C
in neutral, aqueous buffer......................................................................... 103
Figure 3.22 CD spectra of Ipi-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C
in 25 mM SDS.......................................................................................... 106
Figure 3.23 CD spectra of Ipiom-9 at 30 °C, 40 °C, 50 °C, 60 °C, and 70 °C
in 25 mM SDS.......................................................................................... 107
Figure 3.24 CD spectra of AcIpi-9, AcIpiom-9, AcIpidab-9 and Aclpidap
in 25 mM SDS.......................................................................................... 110
Figure 3.25 CD spectra of AcIpi-9, AcIpiom-9, AcIpidab-9 and AcIpidap-9
in CH3CN-TFE (9:1) at 25 °C.................................................................. I l l
Figure 3.26 CD spectra of AcIpi-9, AcIpiom-9, AcIpidab-9 and AcIpidap-9
in buffer.................................................................................................... 1 1 2
Figure 3.27 CD spectra of AcIpi-9, AcIpiom-9, AcIpidab-9 and AcIpidap-9
in CH3CN-H2O (9:1) at 25 °C.................................................................. 113
Figure 3.28 CD spectra of AcIpi-9 in buffer at pH 7, pH 4, and pH 2..........................116
Figure 3.29 CD spectra of AcIpiom-9 in buffer at pH 7, pH 4, and pH 2.....................117
Figure 4.1 Main phosphonamide and thiophosphonamide synthetic targets...............136
xi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Schemes
Scheme 1.1 Enzyme-catalyzed peptide hydrolysis (top) and
enzyme inhibitors (bottom).........................................................................5
Scheme 1.2 Peptide synthesis catalyzed by an antibody..............................................6
Scheme 1.3 Preparation of a phosphonopeptide via an activated P (V)
Species........................................................................................................ 7
Scheme 1.4 Synthesis of hapten precursor via P (V) coupling method.........................9
Scheme 1.5 Modified P (V) approach for attempted synthesis of
hapten precursors....................................................................................... 1 0
Scheme 1.6 Retrosynthetic analysis of phosphonopeptides...........................................11
Scheme 2.1 Retrosynthetic analysis of phosphonamides and thiophos-
phonamides lc-d ........................................................................................30
Scheme 2.2 Activation of H-phosphinates 4 to form phosphonochloridite 3................ 32
Scheme 2.3 Proposed route for phosphonate ester cleavage and phosphon-
amidate formation.......................................................................................34
Scheme 2.4 Synthesis of la-d via Path A or Path B................................................... 36
Scheme 2.5 Synthesis of Cbz-protected thiophosphonamides 12-13 and
phosphonamide 14.....................................................................................42
Scheme 2.6 Synthesis of thiophosphonate diesters 19-20............................................ 43
Scheme 2.7 Synthesis of oxazaphospholine 7 via PS-DIEA resin................................45
Scheme 2.8 Use of non-urethane amine-protecting groups in
phosphonopeptide synthesis...................................................................... 49
Scheme 2.9 Proposed intermediates after deprotonation of
Nbs-protected phosphonochloridite...........................................................49
Scheme 2.10 Cleavage mechanism for Dde-protected amino acid or peptide.................50
Scheme 2.11 Proposed cleavage mechanisms for Dde-protected
phosphonochloridite................................................................................. 50
xii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Scheme 2.12 Use of triphenylphosphine-polystyrene resin in preparation of Id ............54
Scheme 2.13 Synthesis of 1-aminoalkylphosphonous acid 29....................................... 56
Scheme 2.14 Synthesis of Cbz and Nbs-protected H-phosphinate esters....................  57
Scheme 2.15 Synthesis of Dde-protected H-phosphinate esters 22................................ 57
Scheme 3.1 Synthesis of Fmoc-Aib-Aib-OH 6 ............................................................ 82
xiii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Abbreviations













dab 2,4 diaminobutanoic add
dap 2,3 diaminopropanoic add
DBU 1,8-diazobicyclo[4.5.0]undec-7-ene
DCC dicyclohexyl carbodiimide












Et2 0  diethyl ether
EtOAc ethyl acetate
EtOH ethanol
FABMS fast atom bombardment mass spectrometry
FCS fetal calf serum
Fmoc 9-fluorenylmethyloxycarbonyl
Fmoc-Cl 9-fluorenylmethyI chloroformate
GC-MS gas chromatography-mass spectrometry
HATU N-[(dimethylamino)-lH-l,2,3-triazolo[4,5-b]pyridin-l-ylmethylene]-N-
methyl-methanaminium hexafluorophosphate N-oxide
HBTU 0-(benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOAt l-hydroxy-7-azabenzotriazole
HOBt l-hydroxybenzotriazole
HPLC high performance liquid chromatography
HRMS high resolution mass spectrometry
Lys lysine
m multiplet
MALDI matrix assisted laser desorption ionization
MeOH methanol
xv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
MHz megahertz







NMR nuclear magnetic resonance
om ornithine
PAL Peptide Amide Linker
PBS phosphate buffered saline
PEG polyethylene glycol







SDS sodium dodecyl sulfate












Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Abstract
Peptides and peptide analogs are central to the understanding of biological and 
biochemical phenomena as well as in the development of new pharmaceutical agents. 
This research encompasses two classes of peptide mimetics: phosphonopeptides and 
short, amphipathic peptides rich in oc,a-disubstituted amino acids (aaAA). The focus of 
the first part of the peptide analog project was on the preparation of sterically-hindered 
phosphonamide and thiophosphonamide dipeptides. Conditions were developed, based 
on our P(m) synthetic approach, for the preparation of the phosphonamide dipeptides, 
Cbz-CyhGly y  [P (O) (OpNb) NH] Trp-NH2 and Cbz-CyhGly y  [P (O) (OpNb) NH] 
Trp-OMe, which were previously unattainable by P(V) methods. The use of reduced 
phosphorus intermediates also allowed preparation of the related thiophosphonamides, 
Cbz-CyhGly \|f [P (S) (OpNb) NH] Trp-NH2 and Cbz-CyhGly \|f [P (S) (OpNb) NH] Trp- 
OMe. With the P(IH) synthetic strategy we started from an amine-protected H- 
phosphinate amino acid ester and activated, in the presence of 2  equivalents of pyridine, 
with dichlorotriphenylphosphorane to generate a phosphonochloridite, which was treated 
with a diisopropylethylamine to form a proposed, very reactive, oxazaphospholine. The 
oxazaphospholine was coupled to an amine nucleophile followed by oxidation or 
sulfurization. This method was also used to prepare several simpler phosphonamide and 
thiophosphonamide dipeptides and thiophosphonates.
In the second part of this project a homologous series of 9-mer, aaAA-rich 
peptides (and their acetylated versions), which were designed to be amphipathic and 310- 
helical, were prepared using solid-phase synthetic techniques. The peptides were 
composed of 78% aaAAs (one 4-aminopiperidine-4-carboxylic acid (Api) and six
xviii
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aminoisobutyric acid (Aib)). The in situ coupling agent, PyAOP, was used in the 
synthesis. The use of Fmoc-Aib-Aib-OH in the syntheses caused a significant 
improvement in the coupling and overall yields of the peptides. However, the monomer 
Aib had to be incorporated, along with double coupling, for the first two Aibs in each 
peptide’s sequence.
The helix preference of each peptide in different solvent environments were 
investigated as well as each peptide’s antimicrobial activity and cytotoxicity. Significant 
populations of both a- and 3to-helices were observed for the non-acetylated peptides 
under the solvent conditions tested. The 3to-helical, amphipathic design was observed 
best for the acetylated peptides. Most of the peptides exhibited modest activity against E. 
coli and no activity against 5. aureus. The non-acetylated peptides (concentrations < 100 
pM) and the acetylated peptides (concentrations < 200 pM) did not exhibit, based on a 
trypan blue stain procedure, any significant cytotoxicity to normal macrophages.
xix
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Chapter 1 
Introduction
1.1 A Brief Overview of Peptides and Peptide Analogs
Peptides, which are relatively low-molecular weight polymers of amino acids (in 
contrast to high-molecular weight proteins), are present in most life forms. The amino 
acids are linked together by a covalent peptide bond between the carboxyl end of one 
amino acid and the a-amino end of another. Peptides play a key role in a diverse range of 
biological processes. Some examples of peptides found in the human body are 
enkephalins, bradykinin, vasopressin, oxytocin, and glutathione. Enkephalins are 
pentapeptides whose primary function is pain control; they lessen pain sensitivity by 
binding to receptors in certain brain cells. 1' 1' 1'2 Bradykinin, vasopressin, and oxytocin are 
peptide (nonapeptides) hormones that inhibit tissue inflammation, control blood pressure, 
and induce labor in pregnant women, respectively. 1’1 Glutathione is a tripeptide that 
destroys harmful oxidizing agents in the body. 1' 1,1'3
Unfortunately, peptides and proteins also play a pivotal role in many chronic and 
infectious diseases. 1'4' 18 Insulin-dependent diabetes is a disease that is believed to be 
caused by otherwise innocent viral peptides. 14 They mimic peptides found in the human 
body and stimulate the immune system to attack these self-peptides. 14-15 Rheumatoid 
arthritis16 and multiple sclerosis1'7 are other autoimmune diseases where self-peptides are 
erroneously seen as foreign species. Furthermore, the aberrant functioning of proteases, 
which are an important class of enzymes that play key roles in a wide variety of 
biological processes, often lead to physical and mental ailments. 18
1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2
Molecular recognition of a peptide by a macromolecular receptor is crucial to the 
processes or disorders mentioned above. 14*1'9 Therefore, peptides themselves seem to be 
the first obvious candidates to interfere with this action. However, it is often not 
advantageous to use peptides in drug therapy. In general, peptides have poor 
pharmacokinetic properties that limit their use as drugs. If given orally, they are prone to 
degradation by proteases in the stomach as well as poor absorption in the intestinal 
system. 1' 10 Even if peptides are given intravenously, their activity is often short-lived 
because proteolytic enzymes in the blood and in other tissues rapidly degrade them. 111 
The disadvantages of peptide drugs have stimulated an intense quest for peptide 
analogs. 1' 12*1 15
A peptide analog or a peptidomimetic is a compound that mimics the critical 
features (e.g., shape and functionality) of a parent peptide. 1' 16*117 Peptidomimetics are 
often designed to be more stable and sometimes more active than peptides. For example, 
increased proteolytic stability can be achieved by replacing the amide bond by alkene 
bonds (as seen in a vinylogous peptide) 1 18 or placing the amino acid side-chain on the 
nitrogen atom (as seen in a peptoid) . 1 19 It is also desirable for peptide analogs to have 
high-yielding coupling steps that are amenable to automation, which could lead to faster 
exploration of the space of chemical diversity for compounds with the desired 
properties. 1' 11' 1' 12 Presented in Figure 1.1 are examples of several classes of peptide 
analogs; phosphonopeptides and a,a-dialkylated peptides are the foci of this dissertation. 
The general design of both of these peptide mimetics also allows for increased proteolytic 
stability as well as some bioactivity.
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3
1.2 Importance of Phosphonopeptides
Phosphonopeptides (organophosphorus V derivatives) are a significant, stable 
class of biologically active peptide mimics. 12(M'21 In phosphonopeptides, as seen in 
Figure 1.1, the scissile peptide linkage is replaced with a tetrahedral phosphorus ester or
O R,
krRrJW lYO R O Ri
Peptide
H y RJ i  H 9  v
Ri R O Ri R
a,a-disubstituted amino acid-rich peptide
h } y  9 v  ,
H R  H < £ P  H R  H o
phosphono-peptide, X = O, NH
O
iY > A ^ Ny Y i
O R, O R,
Peptoid [Oligo (N-substituted glycine)]
TJ 0  FU TT
0 i  H 0 6.
Oligocarbamate
O R2 jj
Iy nv ^ u"n̂ ŝ y






Figure 1.1 Gasses of peptide analogs
amide moiety group. They emulate high-energy tetrahedral transition states that are 
common to many enzyme-catalyzed pepdde hydrolysis reactions; hence, they are useful 
in the elucidation of enzyme mechanisms and as enzyme inhibitors. 1̂ 2 Such transition- 
state analogs have been employed as effective inhibitors of serine (e.g., chymotrypsin and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
human leukocyte elastase) , 123' 124 metallo (e.g., carboxypeptidase A and angiotensin- 
converting enzyme) , 1'25' 1'26 and aspartyl (e.g., pencillopepsin and HIV proteases) , l1 5 ,127 
proteases (Figure 1.2). Scheme 1.1 is an example of a metallo-protease catalyzing the 
hydrolysis of an amide bond in a model peptide or protein; the high-energy tetrahedral
intermediate is bound more tightly than the substrate. 1.28-1.29 The inhibition of the
metallo-protease by a model phosphonopeptide is also shown in Scheme 1.1; good 
potential inhibitors of the enzyme will bind more tightly than the substrates. 139
H a  ,,o




(X 1 n< r-§[  X OH




H 2  ! H
n  I H n  1 H n
Z-AIa-Ala-Leu y  [(P02*) O] Phe-OCH3
competitive inhibitor of 
pencillopepsin (aspartyl protease)
Figure 12  Phosphonopeptide enzyme inhibitors
Several phosphonopeptides have also shown powerful antibacterial activity. 1"30"132
Allen et al. reported the design and synthesis of the first phosphono-based antibacterial
agent, alafosfalin. 130 Several phosphonopeptide derivatives, based on alafosfalin, have
since been reported. 132 They have been shown to have activity against several bacterial
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species such as Escherichia coli, Staphylococcus aureus, Bacillus subtilis, and Serratia
132marcescens.
More recently, phosphonopeptides have been applied to hapten design for 
generation of catalytic antibodies that possess peptide ligase activity. 133 It is possible to 
generate antibodies with enzymatic activity by choosing haptens that are analogous to the 
transition state of the substrate for a chemical reaction. 1'33*134 When a transition-state 
analogue is employed as a hapten, it induces an array of different antibodies that bind the 
hapten specifically. 1'34 Hirschmann et al. reported the antibody-catalyzed formation of a 
dipeptide; a phosphonate diester hapten was employed (Scheme 1.2) . 133
Zinc protease mechanism
R’NH





Scheme 1.1 Enzyme-catalyzed peptide hydrolysis (top) and enzyme inhibition (bottom)








r o ' r NHz
O R H H o O O O
Proposed intermediate
Hapten used to generate catalytic antibody
Scheme 1.2 Peptide synthesis catalyzed by an antibody 
13 Synthetic Strategies for Phosphonate Esters and Amides
Generally, phosphonate and phosphonamide peptide analogs are prepared by 
coupling a phosphonochloridate (P (V) compound) with an alcohol or amine nucleophile, 
respectively (Scheme 1.3). Phosphonochloridates, for this purpose, have been obtained 
by the reaction of phosphonate diesters with phosphorus pentachloride, 135‘137 by the 
treatment of phosphonate monoesters with thionyl chloride or oxalyl chloride, 115,128,138 
and by oxidative activation of H-phosphinate esters with carbon tetrachloride. 1 39 These 
reactions, phosphonochloridates with alcohol or amine nucleophiles, are usually sluggish 
and low to moderate yielding, which are due, to some extent, to the slow nucleophilic 
attack on the phosphorus (V) center. 140 Moreover, for the amine nucleophiles, the 
amount of HC1 that is produced in the reaction mixtures often interferes with the desired 
coupling process, even if excess base (e.g., EtjN) is employed. 139
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Scheme 13 Preparation of a phosphonopeptide via an activated P(V) species
Improved synthetic methods for preparing phosphonate diesters have been 
reported. Moderate to high and reproducible yields of diesters have been obtained under 
mild conditions with a modified Mitsunobu protocol in which the alcohol was the 
limiting reagent-for possible solid-phase synthetic application-and the modifications 
included an exogenous base and electron deficient phosphines. 141 Also, BOP-mediated 
activation of phosphonate monoesters is an efficient, racemization-free route for 
preparing phosphonate diesters; this procedure is complementary to Campbell’s 
Mitsunobu methodology. 142
Phosphonamides are, in general, more difficult to prepare than phosphonate 
diesters. Nevertheless, Moroder and coworkers1'43 made significant improvements in the 
synthesis of phosphonamidate peptides. They optimized the preparation of phosphono­
chloridates with oxalyl chloride in the presence of catalytic amounts of DMF, which were 
then either employed under AgCN catalysis or converted into the 7-aza-l- 
hydroxybenzotriazole ester for phosphonamide bond formation. However, long reaction 
times ( =14 hrs.) and moderate yields (for some of the desired compounds) were still 
observed. 143 Besides their suggested acid-lability, 122,1'36' 1"37 phosphonamidates’ poor 
synthetic accessibility is severely limiting the use of this interesting class of compounds 
as tools in enzyme chemistry. 1 43
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Hirschmann and co-workers attempted the preparation of the phosphonamide 
hapten precursor (X = NH) in Scheme I.4. 1'33*1'34 Unfortunately, their earnest attempts to 
couple D-tryptophanamide with the phosphonochloridate failed to yield the expected 
phosphonamide even in the presence of AgCN (catalyst). Furthermore, efforts made to 
try to couple the phosphonate monoester with D-tryptophanamide using several different 
kinds of condensing agents such as diphenyl phosphorylazide and BOP reagents were 
unsuccessful. Nevertheless, they were able to couple, under AgCN catalysis, the 
phosphonochloridate with (R)-(+)-P-indolyllactamide to obtain the phosphonate diester 
in yields that were initially variable (0-32%).144 Preparation of the phosphonate diester 
in a reproducible 40 % yield was later achieved by converting the phosphonochloridate 
into a phosphonyltriethylammonium salt prior to the addition of AgCN and (R)-(+)-|3- 
indolyllactamide (Scheme 1.5). The phosphonate diester was subsequently converted 
into a hapten, which was used to induce antibodies that possess peptide ligase activity. 133 
However, the synthesis of the phosphonamide hapten precursor remained elusive.
1.4 Phosphorus (HI) Synthetic Approach
The synthesis of phosphonate esters and amides from H-phosphinates by a novel 
one-pot activation-coupling-oxidation/sulfurization protocol was developed in Hammer’s 
laboratory. 1'45 In this approach phosphonochloridites, activated P(m) species, were used 
in the key coupling step instead of phosphonochloridates, P(V) compounds (Scheme 1.6). 
Since nucleophilic displacement is much faster at a P(III) center than at a P(V) center, 140 
this new synthetic approach has the potential of increasing the yield and efficacy of 
production of phosphonopeptides. This P(m) approach also permits facile design and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9
preparation of phosphonates with a variety of heteroatoms around the phosphorus center 
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Scheme 1.4 Synthesis of hapten precursor via P(V) coupling method
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Scheme 1.5 Modified P(V) approach for attempted synthesis of hapten precursors
Because of their air-stability, the H-phosphinates were envisioned as the ideal 
precursors to the P(m)-based phosphonate synthesis. They could be easily converted to 
the P(m) species with the commercially available dichlorotriphenylphosphorane 
(PhsPCh). Following activation, the phosphonochloridite could be coupled, in the 
presence of base, to an amine or alcohol nucleophile and then oxidized or sulfurized. 
Using this protocol, Fernandez and co-workers were able to prepare about 12 dipeptide
model compounds in moderate to good yields.1.45
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Scheme 1.6 Retrosynthedc analysis of phosphonopeptides
The goal of this part of the research was to develop general conditions, employing 
the P(IH)-based protocol, for preparation of the phosphonamide hapten precursor144 
(described by Hirschmann and coworkers) and related sterically-hindered phosphonamide 
and thiophosphonamide derivatives. Since the P(m) strategy was successful for 
preparation of dipeptide model systems, it was employed to try to increase the yield and 
efficacy of production of our target phosphonodipeptides, which exemplify the 
difficulties many laboratories have encountered in preparing phosphonamidate 
peptides. 133’117'146 We hoped that optimization of this protocol would result in a facile, 
general method (solution- or solid-phase) for preparing simple or complex 
phosphonopeptides so that they may be readily available for biological and medicinal 
applications.
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1.5 Peptide Secondary Structure
The amino acid sequence of a peptide or protein is termed its primary structure; 
however, the local conformation or regular folding pattern of its backbone defines its 
secondary structure. 147 The pair of conformational angles, phi (<(>) and psi (\|f), of each 
amino acid determines the conformation of the main chain of a protein (Figure L.3) . 1 48
%
V%\
Figure 13 Torsional angles of a peptide backbone
The most common secondary structural elements found in proteins are the a-helix, P- 
pleated sheet, and turns or bends. 1-47 The a-helix and P-pleated sheet are periodic 
structures; they possess hydrogen-bonding patterns (main chain NH and CO  groups) that 
repeat at regular intervals. 1-47' 1-48 The a-helix is rodlike and involves only one continuous 
peptide chain, but the P-pleated sheet, which can form a two-dimensional array, can 
include one or more polypeptide chains. 1-47' 148 Besides hydrogen-bonding, the a-helix 
and P-pleated sheet are generally stabilized by hydrophobic effects, Van der Waals 
forces, and electrostatic forces. 149*1-51 The turns in a protein are the stretches or bends 
where the polypeptide chain abruptly changes direction; they often occur at the surface of
or
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proteins. 1'47,1,50 Furthermore, incorporation of turns also allows a-helices and P- sheets to 
be folded back onto themselves. 150 Some polypeptides assume a random coil 
conformation, which is a non-repetitive structure that is flexible and statistically 
random. 1'47 Random coils, however, can form reproducibly in a peptide chain. 151
The a-helix is the most prevalent helical structure found in proteins. 1'48' 151 The 
consecutive residues in an a-helix all have the phi, psi angle pair at approximately -60° 
and -500.1'48 In the a-helix there are 3.6 residues per turn with hydrogen bonds between 
the carbonyl oxygen of residue i and the amide proton of residue i + 4, forming a 13- 
membered ring (Figure 1.4) . 150' 151 The rise per residue of an a-helix is 1.5 A along the 
helical axis, which corresponds to a rise of 5.4 A per turn. 148 Theoretically, an a-helix 
can be either right-handed or left-handed depending on the screw direction of the chain. 
However, right-handed a-helices, which are promoted by L amino acids, are almost 
always observed in proteins. 148,150' 151 A left-handed a-helix is not allowed for L amino 
acids due to the proximity of the side chains and the carbonyl group. 148
The 3io-helix, though less common than the a-helix, accounts for approximately 
10 % of helical structures in proteins. 152' 1-53 The phi, psi angle pair for consecutive 
residues in a 3to-helix is approximately -30° and -50°.154 In 3io-helices there are 3 
residues per turn with hydrogen bonds between the carbonyl oxygen of residue / and 
amide proton of residue i + 3, forming a 10-membered ring (Figure 1.4) . 153' 154 The rise 
per turn in a 3io-helix is 5.8 A, which corresponds to a rise of 1.94 A per residue. A 310- 
helix is therefore slightly longer and tighter than an a-helix. 154

















Figure 1.4 Hydrogen bonding pattern of an a-helix and 3io-helix.
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1.6 Amphipathic a-Helix
In an amphipathic helix one face, along the helix axis, is hydrophilic while the 
opposite face is hydrophobic. 148 The “Schiffer-Edmundson” helical wheel projection 
(two-dimensional) shown in Figure 1.5 is a convenient way to illustrate the amino acid 
sequence of an amphipathic a-helix. In the diagram, P represents the polar residues of 
the hydrophilic face, and N represents the non-polar residues of the hydrophobic face. 
The helical wheel is shown as if looking down the helix axis from the C-terminus to the 
N-terminus. Since one turn in an a-helix is 3.6 residues long, each amino acid can be 
plotted every 360/3.6 = 100° around a circle. 148 The structural arrangement of 
amphipathic a-helices allows them to develop a barrier between non-polar regions of a 
macromolecule or molecular assembly and a polar environment. 1 55 It also provides a 
means for protein-protein interactions via hydrophobic interactions between two 




Figure 1.5 Helical wheel diagram of an amphipathic a-helix.
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Amphipathic a-helices comprise about 50 % of the a-helices found in soluble 
globular proteins. 1-56"1̂ 7 They are also found in fibrous proteins like myosin and 
tropomyosin, DNA-binding proteins, and smaller polypeptides such as hormones and 
venom. 157 Furthermore, amphipathic peptides are exploited as part of the host defense 
system of many organisms, ranging from prokaryotes to humans. 1'57' 1'58 These 
antimicrobial peptides kill bacteria and other microbes presumably by disrupting the cell 
membrane. 157 Several studies have indicated that the amphipathic character of 
antimicrobial peptides plays a significant role in their biological activity. 1'57,1^ 9 In 
addition, even short, de novo peptides (10-16 residues of varying sequences) containing 
the amphipathic a-helix as the only consistent structural feature were shown to have 
comparable antimicrobial activities as longer or native peptides; they also tended to 
exhibit a higher degree of selectivity of bacterial killing over normal mammalian cells. 1 J 9
Many naturally occurring antimicrobial peptides of broadly varying sequence 
have been isolated with amphipathic helical domains as a consistent structural feature.1̂ 9' 
160 Antimicrobial peptides usually contain approximately equal numbers of polar and 
non-polar amino acids within the amphipathic domains and a sufficient number of basic 
residues to provide the peptide an overall positive charge at physiological pH. 159 Some 
antimicrobial peptides display excellent selectivity in destroying bacteria over 
mammalian cells. 159 This selectivity has been ascribed to differences in the cell 
membranes of bacteria and mammals. Bacteria exterior membranes are negatively 
charged, but the exterior membranes of mammalian cells are essentially neutral. As 
stated previously, antimicrobial peptides have an overall positive charge; they might 
therefore preferentially bind to bacteria over mammalian cells. The cholesterol in the cell
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membranes of mammals, which could possibly inhibit membrane disruption by 
antimicrobial peptides, and the lower membrane potential across mammalian cells have 
also been suggested as bases for selectivity of antimicrobial peptides. 159,161
Some examples of natural antimicrobial peptides are melittin, cecropin A, 
magainin 2, and alamethicin. 1 62-163 Melittin, an amphipathic peptide composed of 26 
residues, is extracted from the honey bee, Apis mellifera, 162 Melittin is positively 
charged (+ 6 ); its hydrophobic surface is more extensive than its narrower polar face. It 
exhibits broad spectrum antimicrobial activity at micromolar concentrations, but it is very 
cytotoxic. 139,162 Cecropin A is a 37-residue antimicrobial peptide isolated from the 
North American silk moth, Hyalophora cecropia. It contains two a-helical regions 
extending from residues 5 to 21 (amphipathic region) and 24-37 (largely hydrophobic) 
with the two helical regions lying in two planes that form an angle of 70° to 1000 . 162 
Cecropin A displays excellent antimicrobial activity at concentrations that are not 
cytotoxic toward mammalian cells. 1,59,1'62 Magainin 2  is a 23-residue antimicrobial 
peptide isolated from the skin of the frog, Xenopus laevis. Magainin 2, like Cecropin A, 
exhibits broad spectrum antimicrobial activity at concentrations not cytotoxic toward 
mammalian cells. 1,62 Furthermore, both Cecropin A and Magainin 2 are unstructured in 
aqueous solution but become a-helical in amphipathic media such as cell membranes and 
micelles. Alamethicin is 20-residue linear peptide of the fungus, Trichoderma 
viride. 134,163 It is a member of the peptaibol class of natural antiobiotics, but it is very 
toxic. It is characterized by an acetylated N-termini, a C-terminal alcohol 
(phenylalaninol), and a high percentage of a-aminoisobutyric acid (Aib) residues. It is
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noteworthy that the short peptide, Alamethicin, is highly helical due to the presence of 
the high number (7) of Aib residues. 1-54,163
1.7 Significance of a, a-Dialkylated Amino Acids in Short Peptides
The occurrence of Aib-rich sequences in natural peptide antibiotics and 
membrance-channel forming polypeptides has led to an upsurge of interest in the design 
and synthesis of short, Aib-rich peptides with predictive secondary structure. 164' 169 
Peptides containing Aib tend to favor a helical conformation. Although several 
proteinogenic amino acids are known for promoting helicity in proteins or peptides, the a, 
a-dialkylated amino acid, Aib, is rather unique because it effectively confers high helicity 
on short synthetic peptides of length 8 -1 0 , which is half the length required of most other 
sequences. 1'67 The allowable phi, psi angle pair for Aib occur in two very restricted 
regions, located in the area of (-57°, -47°) and (57°, 47°). These two regions correspond 
to a right-handed a- or 3io-helix and a left-handed a- or 3to-helix, respectively. 1 64,166 
Since the Aib residue is achiral, either the L- or D- configuration is equally possible. 
Chiral residues that have the L- or D- configuration therefore determine the handedness 
of a helix comprised of Aib residues in the sequence. 164
Backbone conformations of Aib-rich peptides may display a 3i0-, a-, or mixed 
3io-/a-helical pattern depending upon critical factors such as peptide length, Aib fraction, 
and amino acid sequence. 164' 165 Karle and Balaram1 64 compiled general conformational 
trends observed for 33 Aib-containing peptides (6-20 residues) in the crystalline state. 
The authors suggested from their study that, in general, a 3io-helical structure is preferred 
for shorter peptides and an a-helical structure for longer peptides. A medium length of 
8-10 was considered to be the 3io/a transition length for peptides possessing 50 % Aib.
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Peptides of a shorter length favor the 3io-helix while longer ones favor the a-helix. Also, 
the study indicated that a large percent (> 50%) of Aib residues in a peptide induces a 
310-helix. Similar findings were also found in other studies conducted on the crystal 
structure of various peptides containing many Aib residues. 164 Basu et al. reported that 
the amino acid sequence also affected the 3io/a-helix equilibrium. Their study suggested 
that the a-helix is favored when two monosubstituted amino acids are next to each other, 
but the 3to-helix, when no two monosubstituted amino acids are next to each other. 165
Studies have also been investigated on the effect of the solvent on the 3io/a-helix 
equilibrium of Aib-rich peptides. Several investigations (theoretical and empirical) 
suggested that solvents with low dielectric constant favor 3io-helical structures, whereas 
solvents with high dielectric constant are inclined to favor a-helical structures.164,167’169' 
172 Until recently, these studies were limited to spectroscopic measurements of 
hydrophobic peptides (e.g., oligomers of Aib) in organic solvents like chloroform and 
dimethylsulfoxide or X-ray structure determinations of peptides crystallized from organic 
solvents. 167,170 Yokum et al. 1 72 reported the design and synthesis of short, amphipathic 
a- and 3io-helices that exhibited their designed structures in an aqueous, membrane-like 
media (25 mM SDS); their peptides contained 60% Aib content and the water- 
solubilizing a, a-disubstituted amino acid, 4-aminopiperidine-4-carboxylic acid (Api). 
They also reported that amphipathic design was primary in controlling the secondary 
structure (helical preference), overriding traditional key factors such as the number of a, 
a-amino acids (aaAA) and the order of the a-amino acids and aaAA in a sequence. 
Toniolo et al. reported the first pure-water-soluble 3io-helical peptides, which were 
comprised mainly of aaAAs and the extremely water-solubilizing, azacrown-
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functionalized a-amino acid, L-2-amino-3[l-(l,4,7-triazacyclononane)]propanoic 
(ATANP) . 169,171
1.8 Synthesis of Short, Helical Peptides
The incorporation of aaAAs into short de novo peptides promotes helical peptide 
structures and increases the peptides resistance to enzymatic hydrolysis, 173 but, until 
recently, the preparation of the peptides, especially peptides with sequential aaAAs, has 
proven to be a very difficult task. 1'74 The aaAA couplings are inherently more difficult 
because of the significantly greater steric bulk caused by the additional substituent on the 
a-carbon. The use of carbodiimides (e.g. dicyclohexyl carbodiimide (DCC) and 
diisopropyl carbodiimide (DIC)), which are traditional amino acid coupling agents, 
results in unsatisfactory yields for aaAA couplings. 175 Even longer reaction times or the 
use of additives such as 1-hydroxybenzotriazole (HOBt) rarely result in good yields for 
the carbodiimide-mediated aaAA couplings. Employing first-generation uranium salts 
(e.g., 0-(benzotriazol-1 -yl)-1,1,3,3-tetramethyIuronium hexafluorophosphate (HBTU)) 
and phosphonium salts (e.g., benzotriazol-l-yloxy-tris(dimethylamine) phosphonium 
hexafluorophosphate (BOP)) along with extended reaction times or application of heat 
also usually yielded only moderate results for aaAA couplings. 1'72,176
Alternate coupling protocols or reagents have been employed in an attempt to 
improve the unsatisfactory results often observed in aaAA couplings. Some of the 
methods or reagents employed are the following: fluorenylmethyloxycarbonyl-JV- 
carboxyanhydrides (Fmoc-NCAs), azirine method (e.g., 2-(dimethylamino) 3,3-dimethyl- 
azirine), and acid chlorides. All of these methods have the potential of producing 
improved synthetic results for aaAA couplings, but their use have been limited because
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of specific drawbacks. The use of Fmoc-NCAs often result in side-product formation and 
moderate to low yields. 1'76 The azirine method is limited because of the post coupling 
acid hydrolysis, which is detrimental to peptides containing acid labile protecting groups, 
often required for the resulting C-terminal amide. 1 65 The use of acid chlorides is very 
effective for coupling aaAAs, but the harsh, acidic conditions employed for the 
formation of acid chlorides also often limit them to amino acids containing no acid labile 
protecting groups. 1'77 Also, the formation of oxazalones, which could lead to 
racemization, is often associated with acid chlorides. Overall, none of these alternate or 
traditional methods are capable of producing sequential aaAA couplings in high yields 
under general, mild conditions, such as that required for high-purity sequences in solid- 
phase peptide synthesis (SPPS) . 1-54
New and improved methods have been developed for efficient coupling of 
sequential aaAAs. Carpino’s acid fluoride coupling was the first method to give high 
yield couplings of sequential aaAAs under mild conditions both in solution and solid 
phase. 177"1'78 In contrast to acid chlorides, a wide range of protection schemes can be 
employed with the mild, acid fluoride method. An Acid fluoride synthesis is usually 
accomplished by coupling a preformed amino acid fluoride (4 equivalents) with the free 
amine of an amino acid in the presence of 2  equivalents of base like NJV- 
diisopropylethylamine (DIEA). Acid fluoride itself is prepared by treating an amine- 
protected amino acid with cyanuric fluoride ( 2  equivalent) and pyridine (1  equivalent) . 179 
In addition, a method for the in situ generation of an amino acid fluoride with 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) and subsequent coupling 
conditions has been developed; good, comparable results have been observed. 180
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More recently, uronium salts based on l-hydroxy-7-azabenzotriazole (HOAt) 
such as {N-[(dimethylamino)-iH-l,2,3-triazolo[4,5-b]pyridin-l-ylmethylene]-N-methyl- 
methanaminium hexafluorophosphate iV-oxide (HATU) have exhibited significant 
advantages for the coupling of sterically hindered amino acids in terms of improved 
coupling yields and acylation rates and decreased racemization. 181*182 Also, the 
phosphonium-based analog of HATU, 7-azabenzotriazol-l-yloxytris(pyrrolidino)phos- 
phonium hexa-fluorophosphate (PyAOP) have also been reported to be very useful for 
the solid-phase preparation of peptides incorporating hindered amino acids. 1 83 Overall, 
both the second generation uranium salt (HATU) and phosphonium salt (PyAOP) are 
excellent reagents for aaAA couplings. However, PyAOP, relative to HATU, is more 
advantageous because of the formation a less toxic side-product (phosphoramide) and 
because excess PyAOP (in contrast to HATU) doesn’t participate in any chain- 
terminating side reactions at the amino terminus. 1 83
1.9 Circular Dichroism Spectroscopy
Several methods such as X-ray crystallography, NMR, electron spin resonance, 
and circular dichroism (CD) spectroscopy have been employed in peptide secondary 
structure determination. 184 However, due to its convenience and reliability, CD has 
become the method of choice for identifying global peptide secondary structure. 1 85 CD 
spectroscopy is a technique that measures the difference in absorbance of right- and left- 
circularly polarized light by an asymmetric substance. 1 86 Peptide secondary structure can 
be determined by CD in the “far-UV” spectral region (180-250 nm); at these wavelengths 
the chromophore is the peptide bond. 185' 1 87 As seen in Figure 1.6, the major categories 
of peptide conformations (random coil, P-sheet, and helices) are distinctly different. 1 88
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The random coil displays a minimum near 195 nm and a maximum near 217 nm, whereas 
the P-sheet is distinguished by a positive band around 195 nm and a negative band 
centered about 217 nm. Both 3io and a-helical peptides give rise to negative CD bands 
around 222 nm (n—mi*) and 207 nm (ti—mi*). A positive band around 191 nm (7t-Mt*) is 
also characteristic of both types of helical peptides, although it is usually much weaker in 
3 io helical peptides. 189 The ratio R of the intensity of the negative bands, where R = 
is a generally accepted parameter used to distinguish a 3io-helix from an 
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Figure 1.6 CD spectra of poly-L-lysine in the a-helical, P, and random conformations. 
CD spectroscopy played an integral role in the general goal for this part of our research 
on peptide analogs. We were primarily interested in the design and efficient synthesis of
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short, amphipathic 3io-helical peptides that are able to retain good antimicrobial activity 
and low cytotoxicity. With CD, we could analyze the solvent (aqueous-organic) effects 
on the 3io-/a- helix equilibrium on our designed, amphipathic 3to-helical peptides, as well 
as correlate observed secondary structure in various media (e.g., SDS and pure water) 
with bioactivity.
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Chapter 2
Synthesis of Phosphonamides and Thiophosphonamides by a One-Pot Activation-
Coupling-Oxidation Procedure
2.1 Introduction
Phosphonopeptides are peptide mimics2 1 1 2  that emulate high-energy tetrahedral 
transition states of enzyme-catalyzed peptide hydrolysis reactions. Thus, they are useful
0  “I  *1 i  ^  dL
as mechanism-based inhibitors of aspartyl and metallo-proteases. Several 
phospho-nopeptides have also shown powerful antibacterial activity.2 7 1 8  More recently, 
these types of compounds have been applied to hapten design for the generation of 
catalytic antibodies that possess peptide ligase activity.2-9 In this chapter we report the 
synthesis of phosphonamide dipeptides la-d (R = Cbz) (Scheme 2.1) in isolated yields up 
to 30 % using our P(m) one-pot activation-coupling-oxidation procedure.2-10 Previous 
attempts to prepare the hapten precursor la  from P(V) phosphonochloridate 2 and D- 
tryptophamide under standard and optimized conditions were unsuccessful, due in part to 




“ • V  p;ci
o-CgH-ji
2 X = 0
3 X = ..
la  X = O, Y = NH2 
lb  X = S,Y = NH2 
1c X = O, Y = OCH3 
Id X = S, Y = OCH3 
R = Fmoc or Cbz
Scheme 2.1 Retrosynthethic analysis of phosphonamides 
and thiophosphonamides la-d
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exemplify the difficulties many laboratories have encountered in preparing phosphon- 
amidate peptides via P(V) coupling protocols.2' 13*16 The P(m) method detailed herein 
using phosphonochloridite 3 as the key intermediate may provide a general approach to 
preparing complex phosphonamide peptide analogs for a variety of applications.
2.2 Results and Discussion
The air-stable precursor used for generation of phosphonochloridite 3 is racemic, 
carbamate-protected H-phosphinate amino acid 4 (Scheme 2.2) as a diastereomeric 
mixture of para-nitrobenzyl (pNb) esters. The H-phosphinate 4, under certain conditions, 
was converted to the phosphonochloridite 3 with the commercially available dichlorotri- 
phenylphosphorane (PI13PCI2). Because the solvent pyridine and the solvent system 
CH2Cl2/Et3N worked well in our model systems,2-10 they were initially employed during 
activation of 4 with PI13PCI2. However, only a small amount of the phosphonochloridite 
3 (3,P = 200 ppm) admixed with several other as yet unidentified products formed. This 
may be due to the amide functionality in 4 being possibly sensitive to the combination of 
PhsPCh with Et3N or pyridine (when used as solvent). PhjPCh in the presence of Et3N is 
known to convert secondary amides to imidoyl chlorides.2-17 Mechanistically, the 
formation of an isocyanate from the carbamate functionality with Ph3PCh/ EtjN is also 
possible. We therefore searched for alternative solvent conditions for the activation step.
In standard P(V) chemistry, successful conversion of a phosphonate monoester to 
the corresponding phosphonochloridate with thionyl or oxalyl chloride is often done in 
the absence of base.2-111*2-12-2-18*2-20 Therefore, in an analogous attempt to improve the 
activation step of our P(HI) protocol, treatment of 4 with PhsPCh was carried out in the 
absence of base. Only two phosphorus signals, 193 ppm (activated P(m) species) and
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40 ppm (Ph3PO+ HCT) resulted. After activation, we proceeded to the next step of 
coupling, followed by oxidation or sulfurization. Several attempts to isolate or purify the 
resulting dipeptides by column chromatography (silica and alumina under various solvent 
conditions) were generally unsuccessful.
pNbO O pNbO
CbzHN^ Ph3PCI2 CbzHN + ph3p 0
c-CjH,, i-CjH,,
4 3
Scheme 2.2 Activation of H-phosphinate 4 to form phosphonochloridite 3
The difficulty in isolation of the phosphonodipeptides from the silica column was 
initially attributed to the general acid lability of phosphonamides.215,2'21’2'22 However, 
only about 0-3 % of the sulfurized species (3lP = 75-80 ppm) sometimes eluted from the 
alumina (basic or neutral) column. Furthermore, triphenylphosphine oxide tended to 
smear the columns; therefore, it was often observed in every collected fraction. 
Oftentimes Ph;jPO was the only substance to elute.
In an effort to find a solution to the synthetic or isolation problems associated 
with preparation of 1, experiments (P (III) protocol) were conducted using 4 and less 
complex nucleophiles like benzyl alcohol, methyl-S-lactate, leucine methyl ester, and 
benzylamine. hi the crude mass spectra (FAB) of these less complex phosphonate esters 
and amides, the parent ions minus the pNb group were readily observed. Further 
examination of the FABMS of the crude reaction mixtures containing our synthetic 
targets la-d also revealed that the major products appeared to be ones in which the pNb 
group had been cleaved off. It was therefore postulated that the pNb group of these
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simple phosphonate derivatives as well as our targets 1  was possibly being cleaved 
during one of the three steps of the P (HQ-based protocol.
I l l  Examination of Activation Reaction
Upon further inspection of 3IP NMR spectra from the activation step without any 
base, it was speculated that the activated species at 193 ppm was not the desired P (ID) 
species 3. In acidic medium the major side product, PI13PO, resonated at 40 ppm, but, 
upon addition of base, it shifts back upfield to 27 ppm, where it normally resonates in 
neutral or basic milieu. Conversely, the activated P (HI) species at 193 ppm, upon 
addition of base, doesn’t move to the downfield chemical shift of 2 0 0  ppm expected in 
basic media. From this simple 31P spectra analysis and difficulties with isolation of la-d, 
we proposed that activation in the absence of base forms 3 but quickly converts, after 
pNb cleavage, to the respective phosphonodichloridite (3IP = 193 ppm); para-nitrobenzyl 
chloride (pNbCl) was also thought to form in this process (Scheme 2.3).
To validate the hypothesis of pNb cleavage during activation, a study was 
conducted on the activation step using 4 and GC-MS analysis of the products. Reaction 
of 4 with PhsPCh in CH2CI2 in the absence of base produced an intense peak 
corresponding to 4-nitrobenzyl chloride (-1:1 ratio with PhjPO). In contrast, when this 
reaction was performed with pyridine present (-1.5 equiv.), the peak corresponding to 4- 
nitrobenzyl chloride was very weak (<5 % the intensity of PhjPO) (Figure 2.1). It was 
therefore concluded that in order to prevent pNb cleavage, the presence of base to 
scavenge generated HC1 during the activation reaction was essential.
The best solvent/base combination for activation of 4 with PI13PCI2 was finally 
determined to be two equivalents of pyridine (~ 3%) in CH2CI2. With one equivalent of
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Scheme 23  Proposed route for phosphonate ester cleavage and phosphonamidate 
formation
(A) PhjPO 
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Figure 2.1 Comparative GC-MS study of activation step. (A) Sample from activation of 
4 in the absence of base with extensive ester cleavage evidence by side-product, pNbCI. 
(B) Sample from activation of 4 in the presence of pyridine with minimum ester 
cleavage. (C) Mass Spectrum of peak -  17 min. (PI13PO). (D) Mass Spectrum of peak 
~ l l  (pNbCI).
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pyridine nearly equal amounts of 3 (3,P = 200 ppm) and the P(IH) species (3lP = 193 
ppm) that resulted from pNb cleavage formed. Furthermore, as the number of equi­
valents of pyridine increased from 2  to huge excess (e.g., pyridide as solvent), the number 
and amount of side-products increased (Table 2.1). However, with the optimized solvent 
condition, very little or no side products were evident from 3IP NMR.
Table 2.1 Phosphonochloridite generation under various solvent 
and base conditions
Solvent Ph3PCl2a Base (equiv.) 31P 8  ppm (ratiof
Pyridine 2.5* Solvent 200 (0.25), 180 (0.05), 165 
(0.04), 158 (0.15), 120 (0.18), 
115 (0.05), 39-41 (0.08), 28 (1))
CH2C12 2.5* NEt3 (2) same as above
CH2CI2 2 .0 * none 193 (0.4), 40* (1)
CH2CI2 1.5* pyridine (1) 200 (0.3), 193 (0.4), 28 (1)
CH2CI2 1 .2 * pyridine (2 ) 200 (0.85), 28 (1)
a Contains 10-20 %Pti3PO
* Represent number of equivalents needed to consume 4 
c Represent intensity of each peak relative to Ph3PO 
d PhjPOTlCr
2.2.2 Coupling Step
The next step of the one-pot procedure was the coupling of 3 to D- 
tryptophanamide 5a or D-tryptophan methyl ester 5b to form the phosphonamidite 6  
(Scheme 2.4, Path A). The major problem initially encountered with the amine coupling 
of 5 to 3 was the formation of an unknown substance (3IP = 180 ppm) that competed with 
the formation of the phosphonamidite 6 . When 5 was added in one portion to the
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phosphonochloridite 3, only the 31P signal around 180 ppm was observed. However, 
when 5 was added over 15-20 minutes, the intensity of the peak ~ 180 ppm and the four 
possible diastereomeric peaks (3IP, 123, 124, 126, 128 ppm) was nearly equal. We 
therefore directed our investigation toward elucidating the identity or properties of that 
unknown species (31P =180 ppm).
CbzHN
c-CgHu





5a Y = NH,




6 a Y = NH2 











pN b(\ ,  .
T  S ' Y 1
c-C6Hu O
la  X = 0 ,Y  = NH2 
lb  X = S, Y = NH2 
lc  X = 0 ,Y  = 0CH3 
Id X = S, Y = OCH3
Scheme 2.4 Synthesis of la-d via Path A or Path B
In the presence of tertiary amines urethane-protected amino acids and peptides are 
known to cyclize to form oxazolones,2'23 which are themselves reactive acylating agents. 
We reasoned that similar cyclization could be occurring with our urethane-protected 
phosphonochloridite 3 to form an oxazaphospholine2' 19 (3lP = 180 ppm). We generated 
the proposed oxazaphospholine 7 (Scheme 2.4, Path B) by adding 1.5 equivalents of the
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tertiary base, diisopropylethylamine (DIEA), to 3. To investigate the reactivity of 7, the 
nucleophile 5a or 5b was added in one portion. After about 15 minutes, two phosphon­
amidite diastereomers preferentially formed, which, after sulfurization or oxidation, 
resulted in 1 as a mixture of two diastereomers (Figure 2.2, Figure 2.3, and Figure 2.4); 
they were isolated using reverse-phased HPLC (Figure 2.5 and Figure 2.6).
oj in in 
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ppm 200 175 150 125 100 75 50 25
Figure 2 2  3lP NMR spectra: a. Reaction of H-phosphinate 4 with PhjPC^ in presence 
of pyridine (2 equiv.) to form phosphonochloridite 3 (-200 ppm); unreacted 4 is -  36 and 
37 ppm and PhsPCU ~ 64 ppm; peak ~ 28 ppm is Ph3PO in each spectrum b. Proposed 
oxazaphospholine 7 (-  180 ppm), c. Species 6 a (~ 123.6 and 124.9 ppm), d. Target lb  
(87.2 and 88.3 ppm), e. Target la  (~ 29 and 30 ppm).
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Figure 23. 3,P NMR Spectra of HPLC-purified la-lb . (A). Cbz-CyhGly \|f [P (0) 
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Figure 2.4 31P NMR spectra of HPLC-purified lc-d. (A). Cbz-CyhGly \jr[P (O) (OpNb) 
NH] Trp-OCH3 lc. (B). Cbz-CyhGly y[P (S) (OpNb) NH] Trp- OCH3 Id.
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Figure 2.5. Analytical HPLC purity check of isolated la  and lb . HPLC was carried out 
on a Supelco 5 pm C-18 reversed-phase column (0.21 x 25 cm) using a mobile phase of 
0.1 M TEAA buffer (pH = 7) and CH3CN (10 % v/v, 0.05 M aqueous TEAA) with a 
gradient of 50-100 % of the organic phase over 50 min and a flow of 1 mL/min. (A). 
Cbz-Cyclohexyl \|f|P (O) (OPNB) NH] Trp-Mfe la; tR= 10.7 min; purity 82 %. (B). 
Cbz-Cyclohexyl \j/[P (S) (OPNB) NH] Trp- NH2 lb; tR= 19.2 min; purity 95 %.
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Figure 2.6. Analytical HPLC purity check of isolated lc  and Id. HPLC was carried out 
on a Supelco 5 tun C-18 reversed-phase column (0.21 x 25 cm) using a mobile phase of 
0.1 M TEAA buffer (pH = 7) and CH3CN (10 % v/v, 0.05 M aqueous TEAA) with a 
gradient of 50-100 % of the organic phase over 50 min and a flow of 1 mL/min. (A). 
Cbz-CyhGly y[P (O) (OpNb) NH] Trp-OMe lc; tR= 17.7 min; purity 90 %. (B). Cbz- 
CyhGIy \|f[P (S) (OpNb) NH] Trp-OMe Id; tR= 29.2 min; purity 95 %.
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It is interesting to note that the activation of the H-phosphinate ester 4 (3IP = 36 
and 37 ppm) resulted in the formation of only one peak (3lP ~ 200 ppm) for the resulting 
phosphonochloridite 3. We proposed that the expected two diastereomers of 3 resonated 
at the same chemical shift. However, the formation of only two diastereomers of 1 
instead of the expected four may be due in part to the formation of only the trans 
conformer (plus its enantiomer) of 7: the observed, one peak (3lP -1 8 0  ppm) of 7 could 
possibly correspond to one pair of enantiomers (e.g., R, S and S, R). The cis conformer 
(e.g., enantiomers R, R and S, S) appears to be more sterically crowded (Figure 2.7); 





Figtire 2.7 Trans and Cis conformer of oxazaphospholine 7
The proposed oxazaphospholine 7 was also coupled to the amine nucleophiles, 
leucine methyl ester and glycine ethyl ester, and the alcohol nucleophiles, benzyl alcohol 
and methyl (5)-lactate. Coupling of 7 to leucine methyl ester 8  and glycine ethyl ester 9 
resulted in the formation of the phosphonamidites 10 (3IP = 124.9, 126.1 ppm) and 11 
(3IP = 126.5 ppm), repectively. Sulfurization of 10 and 11 formed the thiophosphon­
amides 12 (31P = 86.9,88.3 ppm) and 13 (31P = 89.7 ppm), respectively; oxidation of 11
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formed the phosphonamide 14 (3IP = 39.2 ppm) (Scheme 2.5, Figure 2.8). Coupling of 7 
to benzyl alcohol 15 and methyl-S-lactate 16 resulted in the formation of the 
phosphonates 17 (3lP = 178.7 ppm) and 18 (3lP = 179.8, 179.9 ppm), respectively. 
Sulfurization of 17 and 18 formed the thiophosphonamides 19 (3lP = 97.1 ppm) and 20 
(31P = 95.5,96.9 ppm), respectively (Scheme 2.6, Figure 2.9).
7
H-L-‘ Leu-OMe • HC1 
8 CbzH











13 X = S
14 X = 0
Scheme 2.5 Synthesis of Cbz-protected thiophosphonamides 12-13 and 
phosphonamide 14.
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An alternative structure was explored for the phosphitylating agent (3lP = 180 
ppm). We speculated that the observed reactive species could also possibly be analogous 
to the previously unrecognized phosphonyltrialkylammonium salts of Hirschmann and 
co- workers.2' 11' 2' 12 To test that hypothesis, we tried to generate the phosphitylating agent 
(3IP = 180 ppm) by adding the phosphonochloridite 3 to PS-DIEA resin (DIEA attached 
to a polystyrene resin). We reasoned that if a reactive phosphinyltrialkylammonium salt 
forms, then it would remain attach to the resin. However, after the reaction mixture was 
filtered from the resin, the newly formed phosphitylating agent was found in solution, not 
attached to the resin (Scheme 2.7, Path A vs. Path B). Therefore, we concluded that the 
reactive species that resonated around 180 ppm wasn’t a phosphinyltrialkylammonium 
salt but possibly indeed the initially proposed oxazaphospholine 7.
BnOH
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Scheme 2.6 Synthesis of thiophosphonate diesters 19-20
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Figure 2.8 3IP NMR spectra of thiophosphonamides 12*13 and phosphonamide 14 after 
isolation. (A) Compound 12 after isolation by pressure alumina chromatography. (B) 
Compound 13 after isolation by reverse-phase chromatography. (Q  Compound 14 after 
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Figure 2.9 31P NMR spectra of phosphonates 19-20 after isolation. (A) Compound 19 
after isolation by normal-phase chromatography. (B) Compound 20 after isolation by 
reverse-phase chromatography.
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Scheme 2.7 Synthesis of oxazaphospholine 7 via PS-DIEA resin.
To prepare the final products la-d, 12-14, and 19-20 in Table 2.2, we first generated the 
proposed phosphitylating agent 7 from the phosphonochloridite 3 and two equivalents of 
DIEA. Then an amine or alcohol nucleophile was coupled to 7 to form a 
phosphonamidite or phosphonite followed by sulfurization or oxidation with elemental 
sulfur or t-butylhydroperoxide, respectively. Alternatively, we found that by adding two 
equivalents of 5 with 4 equivalents of DIEA to the phosphonochloridite 3 followed by 
oxidation or sulfurization also results in the formation of 1, but, as a mixture of four 
diastereomers instead of two (Figure 2.10). With this method, the proposed oxaza­
phospholine wasn’t observed; however, we strongly believe it still partially formed 
during the coupling step but quickly reacted with 5 to aid in forming the resulting 
diastereomers of la-d.
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Table 2.2 Synthesis of phosphonamides and thiophosphonamides
Entry Nucleophile X Product % yield* 31 p
1 5a 0 la** 18 28.8,29.4
2 5a s lb*b 14 85.3,86.6
3 5b 0 lc** 15 30.5,30.8
4 5b s Id** 30 88.4,87.3
5 8 s 12*,r 28 86.9,88.3
6 9 s 13** 26 89.7
7 9 0 14** 21 39.2








“ Isolated using reversed-phase HPLC 0 characterized by SlP NMR, lH NMR, and MS 
(FAB). c Purified by pressure alumina chromatography. d Purified by flash (silica) 
chromatography. * Isolated yield.
I  .  I  _1_  .  L  L  .  .  t  .  .  .  > • — » ^  «
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Figure 2.10 31P NMR of alternate procedure for preparation of Id. A. Reaction of H- 
phosphinate 4 with PI13PCI2 in presence of pyridine (2 equiv.) to form phosphonochlo­
ridite 3 (-200 ppm); unreacted 4 is -  36 and 37 ppm and PI13PCI2 -  64 ppm; peak -  28 
ppm is PI13PO in each spectrum. B. Coupling of 5b directly to 3 to form phosphon- 
amidites 6b as mixture of diastereomers. C. Sulfurization of 6b to form Id  as a mixture 
of four diastereomers (85.9,86.7,87.2, and 88.3 ppm).




 I I I I I I I I I I I I I I I I I I I I I I  ..............................  I__ I__ I__ I__ I__I__ I__ I
ppm 180 160 140 120 100 80 60 40 20
Figure 2.11 Generation of oxazaphospholine 7 via PS-DIEA resin. A. Reaction of H- 
phosphinate 4 with PI13PCI2 in presence of pyridine (2 equiv.) to form phosphonochlo- 
ridite 3 (~200 ppm); unreacted 4 is ~ 36 and 37 ppm and PI13PCI2 ~ 64 ppm; peak -  28 
ppm is Ph3PO in each spectrum. B. Reaction of PS-DIEA resin (3.68 mmol/g, 2 
equivalent) with 3 to form 7 in solution; no 3lP signal observed on resin after reaction.
2.23 Role of Amine-Protecting Group
If oxazaphospholine formation is undesired (e.g., result in low coupling efficiency 
or racemization of products) in a phosphonopeptide synthesis, the use of a different kind 
of amine-protecting group may be a logical solution. We investigated the non-urethane 
protecting groups 2-nitrobenzenesulfonyl (Nbs) and 5,5-dimethyI-2-acetyl-l,3- 
cyclohexanedione (Dde) (Figure 2.12). According to Miller and Scanlan,2-24 Nbs- 
protected amino acid chlorides are not capable of oxazolone formation. Bycroft et al.2~25' 
226 concluded that the Dde-protecting group precludes racemization via the common 
oxazolone mechanism observed with urethane amine-protecting groups. Both amine- 
protecting groups (Nbs and Dde) can be removed under relatively mild conditions. The 
removal of the Nbs group2'24’2'27 can be accomplished with PhSH/K2CC>3 in DMF and the
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removal of the Dde2*25*2-26 group with 2% hydrazine in DMF. Furthermore, the Dde 
group can be used orthogonally with both Fmoc and Boc protection in solution and solid- 
phase peptide synthesis. We prepared the Nbs- and Dde-protected H-phosphinate amino 
acid esters 21 and 22 and activated them with PI13PCI2 (Scheme 2.8). As with the Cbz- 
protected phosphonochloridite, we also treated the Nbs- and Dde-protected 
phosphonochloridite 23 and 24, respectively, with DIEA. With the Nbs species, a tiny 
peak around 180 ppm along with a myriad of other small peaks (downfield and upfield) is 
usually observed. In this case we believe that deprotonation of the sulfonamide proton is 
occurring which could lead to a variety of other possible side reactions such as 
cyclization to a five- or three-membered ring or possibly some type of polymerization 
reaction (Scheme 2.9). In the case of the Dde-species, no peak was observed around 180 
ppm, but several upfield peaks were observed. We believe that the Dde group may have 
been prematurely cleaved by DIEA, which is a stronger base hydrazine (used to cleave 
Dde) (see Scheme 2.10 and Scheme 2.11). Self-condensation is one side-reaction that 
may have occurred as a result of Dde cleavage.
o
N bs Dde
Figure 2.12 Non-urethane amine-protecting groups
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Scheme 2.9 Proposed intermediates after deprotonation of Nbs-protected 
phosphonochloridite
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Scheme 2.10 Cleavage mechanism for Dde-protected amino add or peptide.
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Scheme 2.11 Proposed cleavage mechanisms for Dde-protected phosphonochloridite
However, coupling 8 (2 equiv. 8 with 2 equiv. DIEA) to the Nbs-protected 
phosphonochloridite resulted in the expectant diastereomeric mixture of 
phosphonamidites 25 (X = ") (Figure 2.13) along with a small peak around 180 ppm 
(proposed oxazaphospholine); the intensity of the latter peak was much less than the 
intensity of the same peak that resulted from the cyclization of the Cbz-protected 
phosphonochloridite. The formation of the oxazaphospholine could be further reduced 
by the slow addition (-15-20 min.) of the nucleophile to Nbs-protected 
phosphonochloridite. With the Dde-protected phosphonochloridite, the peak at 180 ppm
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wasn’t observed during coupling of 8, but the overall coupling reaction (Figure 2.14) 
didn’t proceed as well as the reaction with the Nbs phosphonochloridite.
Although cyclization wasn’t expected with the Nbs-protected 
phosphonochloridite 23, we do believe that it formed to a small extent (evident by 3lP 
~180 ppm) during the coupling of 8 to 23 in the presence of DIEA. Interestingly, in 
contrast to Cbz-protected phosphonochloridite 3, cyclization to the proposed 
oxazaphospholine doesn’t occur to a great extent with the Nbs-protected 
phosphonochloridite upon addition of two equivalents of DIEA (before coupling). Since 
very minimal cyclization is observed with 23 in the presence of DIEA, the Nbs group 
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Figure 2.13 31P NMR spectra of one-pot procedure with Nbs-protected H-phosphinate 
21. A. Reaction of 21 with PI13PCI2 in presence of pyridine (2 equiv.) to form a Nbs- 
protected phosphonochloridite (~197 ppm); peak ~ 28 ppm is PhjPO in each spectrum B. 
Coupling of 8 (2 equiv)/DIEA (2 equiv) to Nbs-protected phosphonochloridite to form 
four phosphonamidites (~ 123-127 ppm);peak ~ 180 ppm corresponds to a proposed 
oxazaphospholine. C. Sulfurization of phosphonamidites to form thiophosphonamides 
(85.4,85.8, 86.2,86.9 ppm); peaks at 75.5 and 76.5 ppm are thiophosphonate acid esters 
that are form from sulfurization of unreacted ester 21 in the mixture.
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Figure 2.14 3tP NMR spectra of activation and coupling step of one-pot procedure with 
Dde-protected H-phosphinate 22. A. Reaction of 22 with PhsPCfe in presence of pyridine 
(2 equiv.) to form a Dde-protected phosphonochloridite (-196 ppm); peak -  28 ppm is 
PI13PO in each spectrum B. Very poor coupling of 8 (2 equiv)/DEEA (2 equiv) to Dde- 
protected phosphonochloridite to form barely noticeable coupling species -  123 ppm.
The 3lP spectra in Figures 2.10 and 2.13 resemble each other. In Figure 2.10, the 
oxazaphospholine 7 wasn’t purposely generated, like in Figure 2.2, before amine- 
coupling. However, we strongly believe that it still partially formed during coupling (2 
equiv. of 5b with 4 equiv. of DIEA) but quickly reacted with the amine nucleophile to 
form the diastereomeric mixture of phosphonamidites. This is based on the following 
observation: when two equivalents of 5b along with only two equivalents of DIEA was 
allowed to react with the phosphonochloridite 3, 3IP peaks corresponding to both the 
oxazaphospholine 7 and the expected diastereomeric mixture of phosphonamidites 
formed to a substantial extent. Conversely, based on data explained above, the formation 
of an oxazaphospholine plays a very minimal, if any, role during the coupling step of a 
Nbs-protected phosphonochloridite. Nevertheless, in both Figure 2.10 and Figure 2.13, 
thiophosphonamides, as a mixture of four diastereomers, is observed.
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2.2.4 Use of Resin-bound PhjPCh
We investigated the potential of a triphenylphosphine-polystyrene resin, on which 
the activating agent PI13PCI2 can be generated, in the synthesis of our compounds. We 
were attracted to the resin-bound PI13PCI2 because one of the major contaminants, PI13PC), 
of our one-pot procedure would remain attached to the resin after filtration. The resin- 
bound PhjPCk2-28 was prepared by treating the PS-PPh3 resin (in glovebox) with one-half 
equivalent of triphosgene (Figure 2.15). As with our solution-phase synthesis, we 
initially used two equivalents of pyridine with the H-phosphinate ester 4 during activation 
with the resin. However, only a tiny activation peak along with other peaks around 19, 
35-40, and 165 ppm were observed. Basically, the same types of spectra were observed 
when 1-1.5 equivalents of base were used during activation. Because the reactions were 
performed in a glovebox under argon pressure, we reasoned that much less base is 
probably required during activation because of possible removal of some of the generated 
HC1 by the continuous flow of argon. The activation reaction was then tried with only 
0.5 equivalent of pyridine. One peak at 195 ppm resulted. D-Tryptophan methyl ester 
was added to the filtered solution containing the activated species (3tP, 195 ppm). Two 
coupling peaks (—135 and 136 ppm) resulted (noisy baseline). After sulfurization, a tiny 
peak (-80 ppm) corresponding to the sulfurized species along with several upfield peaks 
were observed (Figure 2.16 and Scheme 2.12). FABMS of the crude reaction mixture 
indicated a tiny m/e peak corresponding to the desired compound minus the pNb group. 
Therefore, ester cleavage must have occurred during the activation step. Nevertheless, 
the use of this resin appears to be very promising for the facilitation of the synthesis and
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partial purification of phosphonopeptides once the activation conditions has been clearly 
determined or optimized.
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Scheme 2.12 Use of triphenylphosphine-polystyrene resin in preparation of Id
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Figure 2.15 Generation of resin-bound PhjPCh. A. Triphenylphosphine (-6.4 ppm) 
polystyrene resin contaminated with small amount of Pti3PO (27.2 ppm). B. Reaction of 
Ph2P-PhPS with triphosgene to form resin-bound PhjPCh (60.7 ppm).
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Figure 2.16 31P NMR spectra of one-pot procedure with resin-bound PhsPCh. A. 
Reaction of H-phosphinate ester 4 with CfePPhr-PhPS. B. Coupling products (~ 135 and 
136 ppm) resulting from the addition of D-tryptophan methyl ester to the activated 
species (195 ppm); unidentified side-product (28 ppm). C. Sulfurized product (81.8 
ppm), determined to be Id minus the pNb group.
2.2.5 Synthesis of Protected a-Amino-Alkyl-H-Phosphinate Esters
The 1-aminoallcylphosphonous acid 29 was the starting point for the synthesis of 
the amine-protected H-phosphinate amino acid esters. Compound 29 was prepared 
according to a procedure adapted from Baylis et al.2'29 Reaction of the hypophosphonite 
salt 27, which is formed from a reaction of hypophosphorus with benzhydrylamine, with 
cyclohexane aldehyde produced the diphenylmethylaminoalkylphosphonous acid 28. 
The latter acid was subsequently deprotected in refluxing HBr to afford 29 in 61% yield 
(Scheme 2.13).
Scheme 2.14 outlines the synthesis of Z- or Cbz-protected phosphonous acid 30 
and Nbs-protected phosphonous acid 31. A procedure developed by Dumy et al230 was
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employed. They were prepared primarily by adding a solution of N-(benzyloxy- 
carbonyl) succinimide or 2-nitrobenzenesulfonyl chloride in dioxane to a solution of 29 
in water at a controlled pH (9-9.5 using 4 N NaOH). Compound 30 and 31 were obtained 
in 77% and 76% yield, respectively.
Dde-protected phosphonous acid 32 was prepared according to a procedure 
described by Bolin et al.231 In general compound 29 and TMS-C1 were refluxed in 
CH2CI2 for 2 hours and then, after cooling to 4 °C, 5,5-dimethyl-2-acetyl-l,3- 
cyclohexanedione and DIEA were added. Compound 32 was obtained in a 37% yield.
Esterification of the protected phosphonous acids 30 and 31 (Scheme 2.14) and 32 
(Scheme 2.15) were prepared according to a procedure described by Sampson and 
Bartlett.2'32 To a solution of 30, 31, or 32 in CH2CI2 was added EDC. The H- 
phosphinates 4, 21, and 22 were formed as mixture of two diastereomers in yields of 












Scheme 2.13 Synthesis of 1-aminoalkylphosphonous acid 29
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Scheme 2.15 Synthesis of Dde-protected H-phosphinate ester 22
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23 Conclusions
We developed conditions, based on a one-pot activation-coupling-oxida-
•y m
tion/sulfurization protocol, for preparation of sterically hindered phosphonamide and 
thiophosphonamide dipeptides. It was determined via a GC-MS Study that the presence 
of 2 equivalents of pyridine during activation of our H-phosphinate amino acid ester 4 
with PhsPCh was necessary to prevent ester cleavage; however, using excess base (more 
than 2 equivalents) or a base that is too strong (e.g., triethylamine) could result in the 
formation of several side-products (evident from 31P NMR). We proposed that an 
oxazaphospholine was forming during the coupling step and was competing with the 
formation of the desired phosphonamidites. After discovering that it was a reactive 
phosphitylating agent, it was purposely generated by addition of DIEA to 3 before 
addition of a nucleophile. This coupling route generally led to the formation of two 
coupling, diastereomeric products instead of the possible four. This was attributed to, in 
part, to the formation of only the trans conformer (plus its enantiomer) of the 
oxazaphospholine 7. Oxidation and sulfurization were easily accomplished with t- 
butylhydroperoxide and elemental sulfur, respectively. Using our developed conditions, 
we prepared the previously inaccessible phosphonamide la  (hapten precursor) and 
related derivatives lb-d. We also applied our method to the preparation of the 
thiophosphonates 19-20, thiophosphonamides 12-13, and phosphonamide 14. Compound 
12 and 19 were purified by flash chromatography, but the other products were purified by 
reverse-phase HPLC. All of the final products were characterized by 3IP NMR, *H 
NMR, and FABMS.
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2.4 Experimental Material 
2.4.1 Technical Information
Unless otherwise indicated, materials were purchased from commercial suppliers and 
used without further purification. All reactions were performed in dry glassware under 
an atmosphere of argon. Triethylamine was dried by refluxing over CaH2 and distilling 
directly onto dry molecular sieves (3A). Anhydrous dichloromethane, pyridine, and 
diisopropylethylamine were purchased from Aldrich. Dichlorotriphenylphosphine (95 % 
purity, Aldrich) was stored and manipulated in a dry box. NMR spectra were obtained 
either on a Bruker AC-250 (lH, 3,P) or AC-400 (lH, 31P) spectrometer. All 31P NMR 
spectra were externally referenced against 85 % H3PO4. Gas chromatography was 
performed on a Hewlett Packard 5971A instrument with a crosslinked capillary column 
(10m x 0.53mm, 2.0 urn film thickness) and the following temperature programming: 
Tinitiai 40 °C for 2 minutes then 35 °C/min. up to Tr,nai 270 °C. Preparative HPLC was 
carried out on a Waters 15-pm Deltapak C4 column (25 x 100 cm) using a mobile phase 
of acetonitrile (10 %, v/v, 0.05 M aqueous triethylammonium acetate) and 0.1 M 
ammonium acetate buffer and a gradient of 50-100 % of the organic phase over 1 hour. 
Mass spectrometry (FABMS) was performed at Louisiana State University and 
University of Nebraska-Lincoln Mass Spectrometry facilities. Elemental analyses were 
performed by MHW Laboratories (Phoenix, AZ).
2.4.2 General Procedure
At room temperature, a solution of dichlorotriphenylphosphorane (60 mg, 0.18 
mmol) in dichloromethane (0.28 mL) was added to a solution of the H-phosphinate 
amino acid ester 4 (0.15 mmol) in CH2CI2 (0.7 mL) and pyridine (0.023 mL, 0.29 mmol).
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After 30 minutes, diisopropylethylamine (0.22 mmol) was added to the reaction mixture 
followed, after 15 minutes, by the addition of the nucleophile (0.29 mmol for amines, 
0.22 mmol for alcohols) in one portion. After an additional 15 minutes, elemental sulfur 
(5 mg, 0.15 mmol) or anhydrous t-butyl peroxide (5.5 M in decane, 0.04 mL, 0.22 mmol) 
was added. About 30 minutes later the reaction mixture was concentrated, and the 
resulting residue was triturated with ethyl acetate (3x2  mL). The combined ethyl acetate 
fractions were washed with NaHCC>3 ( 2 x 3  mL) and brine (6 mL), dried with Na2SC>4, 
and then evaporated to give an oily residue. The compounds were isolated using 
reversed-phase HPLC (except were noted) and characterized by 31P NMR, lH NMR, and 
FABMS.
2.4.3 Synthesis and Characterization of 1 -Amino-1 - CyclohexyImethane- 
phosphonous acid
The following compounds were obtained and used in the preparation of 
compound 29.
AKdiphenylmethyl) ammonium phosphonite (2 7 )228
Anhydrous hypophosphorus acid (5.94 g, 90 mmol) was dissolved in ethanol (225 
mL). Benzhydrylamine (15.5 mL, 90 mmol) was then added to the reaction flask and 
stirred for 30 minutes. The solvent was removed with rotary evaporation, and the white 
phosphonite crystals were dried under high vacuum. Yield: 22 g (98%). 3IPNMR(101 
MHz, EtOH) 1.06 ppm.
1-benzhydryiamino-l-cyclohexylmethanephosphonous acid (28)
The phosphonite salt 27 (4.95 g, 19.79 mmol) and cylcohexane carboaldehyde 
(2.40 mL, 19.79 mmol) were dissolved in absolute ethanol, and the reaction mixture was 
heated at reflux for 4 hours. A precipitate of the diphenylmethylaminophosphonous acid
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formed upon cooling of the solution. The precipitate was collected by filtration, washed 
with ethanol and ether, and dried under high vacuum. Yield: 3.73 g (55%). 3lP NMR 
(101 MHz, DMSO) 27 ppm.
l-amino-l-cyclohexylmethanephosphonous acid (29)
An excess of 48% HBr (19 mL) was added to a flask containing the phosphonous 
acid 28 (3.73 g, 10.89 mmol). The mixture was refluxed for 1 hour and 30 minutes. The 
reaction solution was allowed to cool and then taken up in water (30 mL) and washed 
with ether (3 x 10 mL). Rotary evaporation removed the water, and the resulting solid 
was dissolved in methanol (60 mL). Then propylene oxide was added until precipitation 
started. The white precipitate was collected by filtration, washed with ethanol and ether, 
and then dried under high vacuum. Yield: 1.17 g (61%). lH NMR (250 MHz, D2O) 1.35 
(m, 11H, c-CfiHu), 2.98 (m, 1H, CH), 7.15 (d, Jph = 525 Hz, 1H, PH) ; 3lP NMR(101 
MHz, D2O) 18 ppm. FABMS (glycerol) m/e 178.2 (M + H)+; C, 47.46; H, 9.01; N, 7.90; 
found C, 47.65; H, 8.81; N, 7.91.
2.4.4 Synthesis and Characterization of Protected 1-Amino-1- 
Cydohexylmethanephosphonous acids
l-[A-(benzyloxycarbonyI)amino]-l cyclohexylmethanephosphonous acid (30)
The phosphonous acid 29 (0.567 g, 3.20 mmol) was taken up in H2O (8 mL). The
acid dissolved after the pH was adjusted to about 9.5 with 4N NaOH. Then a solution of
N-(benzyIoxycarbonyloxy)succimide (0.867 g, 3.52 mmol) in dioxane (4 mL) was added
over a period of 15 minutes. The pH was periodically checked and adjusted to 9.5. After
stirring at room temperature for six hours, the reaction mixture was extracted with ether
( 2 x 6  mL). 6 N HC1 (12 mL) was added to the aqueous phase. The white precipitate
was collected by filtration and was dried under high vaccum. Yield: 0.769 g (77%). lH
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NMR (250 MHz, CD3OD) 1.35 (m, 11H, c-QsHn), 3.45 (m, 1H, CH), 5.05 (s, 2H, 
PhCH2>, 5.38 (br s, 1H, NH), 7.12 (d, Jra = 575 Hz, 1H, PH) ) 7.33 (m, 5H, Ph); 3lP 
NMR (101 MHz, CD3OD) 30 ppm. FABMS (glycerol) m/e 311.7 (M + H)+; C, 58.01; 
H, 6.70; N, 4.50; found C, 57.81; H, 6.61; N, 4.55.
l-[A-(2-nitrobenzenesulfonyI)amino]-l cyclohexylmetbanephosphonous add (31)
The phosphonous add 29 (0.682 g, 3.85 mmol) was taken up in H2O (10 mL). 
The add dissolved after the pH was adjusted to about 9.5 with 4N NaOH. This solution 
was brought to 4 °C , and then a solution of 2-nitrobenzenesulfonyl chloride ( 0.939 g,
4.24 mmol) in dioxane ( 4 mL) was added over a period of 15 minutes. The pH was 
periodically checked and adjusted to 9.5. After stirring at 4 °C for six hours, the reaction 
mixture was allowed to warm to room temperature. It was extracted with ether ( 2 x 6  
mL). 6  N HC1 (14 mL) was added to the aqueous phase. The white precipitate was 
colleded by nitration and was dried under high vaccum. Yield: 1.07 g (94%). *H NMR 
(250 MHz, DMSO) 1.53 (m, 11H, c-QHn), 3.25 (m, 1H, CH), 4.85 (d, Jra = 525 Hz, 
1H, PH), 8.12 (m, 4H, Ph), 8.56 (d, 1H, NH), 3lP NMR (101 MHz, DMSO) 30 ppm. 
FABMS (3-NBA) m/e 363.0 (M + H)+; C, 43.11; H, 5.25; N, 7.73; found C, 42.90; H, 
5.50; N, 7.69.
l-[iV-(4,4-dimethyl-2,6-dioxocyclohexylidene ethyl) amino]-l- 
cyclohexylmethanephosphonous add  (32)
The phosphonous add 29 (0.823 g, 4.65 mmol) was placed in a flask equipped
with a condenser, heating mantle, and an argon inlet Dry CH2CI2 (12 mL) was added to
the reaction vessel and stirred vigorously. TMS-C1 (1.18 mL, 9.31 mmol) was added in
one portion. The mixture was refluxed for 2 hours and then cooled in an ice bath. DIEA
(1.45 mL, 837 mL) and 2-acetyldimedone (0.564 g, 3.10 mmol) were added in
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succession. The reaction mixture was stirred with cooling for 20 minutes and then 
warmed to room temperature for 2 hours. The reaction mixture was concentrated and 
then distributed between Et2 0  (25 mL) and 2.5% NaHC03 (50 mL). The aqueous layer 
was extracted with 2 x 20 mL of Et2 0 . The aqueous layer was then acidified to pH 2 
with 1 N HC1 and extracted with 3 x 15 mL of EtOAc. The combined aqueous layers 
were then dried over Na2S0 4 , filtered, concentrated, and dried in vacuo. Appropriate 
solvents were used to recrystallized the final product. Yield after recrystallization:
0.40 g (37%). *H NMR (250 MHz, DMSO) 0.98 (s, 6 H, (CHsh) 1.53 (m, 11H, c-QsHn),
2.25 (s, 3H, CH3), 2.50 (s, 4H, 2 CH2) 4.15 (m, 1H, CH), 7.00 (d, JPH = 500 Hz, IH, PH),
13.5 (d, 1H, NH), 3lP NMR (101 MHz, DMSO) 24 ppm. FABMS (3-NBA) m/e 342.1 
(M + H)+‘» C, 59.80; H, 8.21; N, 4.10; found C, 59.73; H, 8.37; N, 3.99.
2.4.5 Synthesis and Characterization of Protected 1-Amino-l-Cyclohexylmethane- 
H-Phosphinate Esters
l-[7V-(benzyIoxycarbonyl)amino]-l-cyclohexylmethanephosphonous acid, 
p-nitro benzyl ester [Cbz-CyhGly y  [POH(OpNb)] (4)
According to the procedure described by Sampson and Bartlett, EDC (0.698 g,
3.64 mmol) was added to a solution of the Cbz-protected phosphonous acid 30 (0.566 g,
1.82 mmol) and para-nitrobenzyl alcohol (0.279 g, 1.82 mmol) in anhydrous CH2CI2 (10
mL). After stirring at room temperature for 10 hours, the solution was diluted with
EtOAc (100 mL), washed with saturated KH2PO4 (2 x 50 mL) , saturated NaHC03 (50
mL), and brine (50 mL), dried over Na2S0 4 , filtered, and evaporated to dryness. A white
powder was obtained. Yield: 0.67 g (82%). lH NMR (250 MHz, CDC13) 1.38 (m, 11H,
c-CeHn), 3.92 (m, 1H, CH-P), 5.10 (s, 2H, CH2OOC), 5.42 (d, 2H, CH2OP), 5.44 (br s,
IH, NH), 7.12 (d, JPH = 560 Hz, IH, P-H), 7.33 (m, 5H, Ph), 7.89 (d, 2H, Ph-N02), 8.18
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(d, 2H, Ph-N02); 3,P NMR (101 MHz, CDC13) 36.1 and 37.1 ppm (1:1.1); FABMS
(NBA) m/e 447.8 (M + H)+; C, 59.22; H, 5.83; N, 6.27; found C, 59.36; H, 5.89; N, 6.15.
l-[iV-(2-nitrobenzenesuIfonyl)amino]-l cyclohexylmethanephosphonous acid, 
p-nitro benzyl ester (2 1 )
To a solution of the NBS-protected phosphonous acid 31 (0.615 g, 1.70 mmol)
and para-nitrobenzyl alcohol (0.260 g, 1.70 mmol) was added EDC (0.487 g, 2.54 mmol)
in anhydrous CH2CI2 (10 mL). After stirring at room temperature for 10 hours, the
solution was diluted with EtOAc (100 mL), washed with saturated KH2P04 (2 x 50 mL),
saturated NaHC0 3  (50 mL), and brine (50 mL), dried over Na2S04, filtered, and
evaporated to dryness. A white powder was obtained. Yield: 0.67 g (94%). lH NMR
(250 MHz, CDCI3) 1.55 (m, 11H, c-QHu), 3.85 (m, IH, CH-P), 5.20 (m, 2H, CH2OP),
5.35 (d, JPH= 510 Hz, IH, P-H), 7.85 (d, 2H, Ph-N02), 8.20 (m, 4H, PhS02) 8.35 (d, 2H,
Ph-N02) 8.62 (s, IH, NH); 31P NMR (101 MHz, CDC13) 35.5 and 36.5 ppm; FABMS (3-
NBA) m/e 498.1 (M + H)+; C, 48.30; H, 4.83; N, 8.50; found C, 48.44; H, 5.00; N, 8.57.
l-[iV-(4,4-dimethyl-2,6-dioxocycIohexylidene ethyl) amino]-l- 
cyclohexylmethanephosphonous acid, para-nitrobenzyl ester (2 2 )
To a solution of the Dde-protected phosphonous acid 32 (0.133 g, 0.389 mmol)
and para-nitrobenzyl alcohol (0.0596 g, 0.389 mmol) was added EDC (0.170 g, 0.887
mmol) in anhydrous CH2CI2 (5 mL). After stirring at room temperature for 10 hours, the
solution was diluted with ethyl acetate (50 mL), washed with saturated KH2P04 (2 x 25
mL), saturated sodium bicarbonate (25mL), and brine (25 mL), dried over Na2S04,
filtered, and evaporated to dryness. A white powder was obtained. Yield: 0.11 g (57%).
'H NMR (250 MHz, DMSO) 1.1 (s, 6 H, (CHsh) 1.50 (m, 11H, c -C ^n ), 2.35 (s, 3H,
CH3), 2.62 (s, 4H, 2CH2) 4.15 (m, IH, CH), 5.25 (m, 2H, CH2Ph), 7.15 (d, Jph = 530 Hz,
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1H, PH), 7.8 (d, 2H, PhN02), 8.44 (d, 2H, PhN02), 14.1 (br s, IH, NH), 3lP NMR (101 
MHz, DMSO) 32.9, 34.4 ppm. FABMS (3-NBA) m/e 477.1 (M + H)+; C, 60.51; H, 
6.93; N, 5.88; found C, 60.69; H, 7.05; N, 5.86.
2.4.6 Preparation of Oxazaphospholine 7 using PS-DIEA Resin
In a glovebox, the phosphonochloridite 3 (0.05 g, 0.11 mmol) in CH2CI2 (0.5 mL) 
was added to a suspension of PS-DIEA resin (3.68 mmol/g (loading), 0.06 g, 0.21 mmol) 
in dichloromethane. The reaction mixture stirred at room temperature for 30 minutes. 
Then the resin was filtered and washed with anhydrous CH2CI2 (3 x 0.2 mL). Major 3lP 
NMR (101 MHz, CH2CI2) peaks of filtrate; 180 ppm (proposed oxazaphospholine 7), 27 
ppm (triphenylphosphine oxide). No signal was detected on the solid support by gel 3>P 
NMR.
2.4.7 Synthesis and Characterization of Complex Phosphonamide and 
Thiophosphonamide Dipeptides
Cbz-CyhGly y  [P (O) (OPNB) NH] Trp-NH2 (la)
It was prepared according to the general procedure. Yield: (18%). lH NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-QHu), 3.2 (m, 2H, CH2-indole), 4.0 (m, IH, CH-P), 4.5
(m, IH, CHCONH2), 5.1 (m, 4H, CH2OOC + CH2OP), 5.7 (m, 3H, NHP + NH2), 6.5 (br
d, IH, NHCO), 7.2 (m, 4H, indole), 7.4 (d, IH, vinylic), 7.6 (m, 5H, O f t ) ,  7.7 (d, 2H,
Ph), 8.2 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 3lP NMR (101 MHz, CD3CN) 28 and 29
ppm. FABMS (3-NBA) m/e 648.2 (M + H)+.
Cbz-CyhGly y  [P (S) (OPNB) NH] Trp-NH2 (lb)
It was prepared according to the general procedure. Yield: (14%) lH NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-CsHu), 3.2 (m, 2H, CH2-indole), 4.0 (m, IH, CH-P), 4.5
(m, IH, CHCONH2), 5.1 (m, 4H, CH2OOC + CH2OP), 6.0 (m, 3H, NHP + NH2), 6.5 (br
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d, 1H, NHCO), 7.1 (m, 4H, indole), 7.3 (d, IH, vinylic), 7.5 (m, 5H, QHs), 7.7 (d, 2H, 
Ph), 8.1 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 3lP NMR (101 MHz, CD3CN) 28 and 29 
ppm. FABMS (3-NBA) m/e 664.1 (M + H)+.
Cbz-CyhGly y  (P (O) (OPNB) NH] Trp-OMe (lc)
It was prepared according to the general procedure. Yield: (15%) lH NMR (250 
MHz, CD3CN) 1.5 (m, 11H, c-CeH,,). 3.3 (m, 2H, CH2-indoIe), 3.5 (s, 3H, OCH3), 3.7 
(m, IH, CH-P), 4.3 (m, 2H, CHCOOCH3 + PNH), 4.9 (m, 4H, CH2OOC + CH2OP), 5.8 
(dd, IH, NHOC), 7.0 (m, 4H, indole), 7.2 (d, IH, vinylic), 7.5 (m, 5H, QsHs), 7.7 (d, 2H, 
Ph), 8.1 (d, 2H, Ph) 9.3 (br s, IH, NH-indole); 3,P NMR (101 MHz, CD3CN) 28 and 29 
ppm. FABMS (3-NBA) m/e 663.2 (M + H )\
Cbz-CyhGly y  [P (S) (OPNB) NH] Trp-OMe (Id)
It was prepared according to the general procedure. Yield: (30%) ‘H NMR (250 
MHz, CD3CN) 1.5 (m, 11H, c-CeHn), 3.2 (m, 2H, CH2-indole), 3.6 (s, 3H, OCH3), 4.1 
(m, IH, CH-P), 4.4 (m, 2H, CHCOOCH3 + PNH), 4.9 (m, 4H, CH2OOC + CH2OP), 5.7 
(dd, IH, NHCO), 7.2 (m, 4H, indole), 7.4 (d, IH, vinylic), 7.6 (m, 5H, CsHs), 7.7 (d, 2H, 
Ph), 8.2 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 31P NMR (101 MHz, CD3CN) 28 and 29 
ppm. FABMS (3-NBA) m/e 678.2 (M + H)+.
Synthesis of Cbz-CyhGly y  [P (S) (OPNB) NH] Trp-OMe (Id) using PS-PhjPCU
In a glovebox, the H-phosphinate ester 4 (0.05 g, 0.11 mmol) in CH2C12 (lmL) 
and pyridine (4 pL, 0.06 mmol) was added to the PS-Pti3PCl2 resin (1.24 mmol/g, 0.2 g, 
0.176 mmol, Argonaut Technologies), which was suspended in CH2C12 (~ 1 mL). The 
reaction mixture was periodically stirred for 1.5 hours, and then the activated species was 
filtered from the resin. 31P NMR (101 MHz, CT^Cl^ of activated species: 195 ppm.
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Under argon, a solution of D-tryptophan methyl ester (0.04 g, 0.16 mmol) in CH2CI2 (0.5 
mL) was added dropwise over 15 minutes to the activated species. After 30 minutes, a 
31P NMR spectrum was taken. The coupling peaks resonated around 135 and 137 ppm. 
To the resulting phosphonamidites was added elemental sulfur (3 mg, 0.11 mmol). The 
sulfurized species resonated around 81 ppm. FABMS (NBA) m/e 541.2 (Desired mass- 
pNb).
2.4.8 Synthesis and Characterization of Thiophosphonamides, Phosphonamides, 
and Thiophosphonates
Cbz-CyhGly y  [P (S) (OPNB) NH] Leu-OMe (12)
It was prepared according to the general procedure (0.23 mmol scale) and purified
by pressure alumina chromatography using EtOAc-Hexane (1:1) as the eluent. Yield: 39
mg (28%). ‘HNMR (250 MHz, CD3CN) 0.88 (d, 6 H, (CH3)2), 1.20 (m, IH, CH(CH3)2),
1.73 (m, 11H, c-QsHu), 3.18 (m, 2H, CH2), 3.62 (s, 3H, OCH3), 4.14 (m, IH, CH-P), 4.4
(m, IH, CHCOOCH3 + PNH), 5.02 (m, 4H, CH2OOC + CH2OP), 5.87 (d, IH, NHCO),
7.36 (m, 5H, CeHs), 7.57 (d, 2H, Ph), 8.22 (d, 2H, Ph); 31P NMR (101 MHz, CD3CN)
86.9 and 88.3 ppm. FABMS (3-NBA) m/e 606.3 (M + H)+.
Cbz-CyhGly y  [P (S) (OPNB) NH] Gly-OEt (13)
It was prepared according to the general procedure (0.14 mmol scale). Yield: 20
mg (26%). lH NMR (250 MHz, CD3CN) 0.95 (d, 3H, CH3), 1.65 (m, 1 IH, c-OH,,), 2.75
(m, 2H, CH2), 3.98 (m, IH, CH-P), 4.23 (q, 2H, OCH2CH3), 5.02 (m, 3H, CH2OOC +
PNH), 5.52 (s, 2H, OCH2Ph), 5.89 (d, IH, NHCO), 7.36 (m, 5H, CsHs), 7.50 (d, 2H, Ph),
8.15 (d, 2H, Ph); 3,P NMR (101 MHz, CDsCN) 89.7 ppm. FABMS (3-NBA + Li) m/e
570.2 (M + Li)+.
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Cbz-CyhGly y  [P (O) (OPNB) NH] Gly-OEt (14)
It was prepared according to the general procedure (0.14 mmol scale). Yield: 16 
mg (21%). ‘H NMR (250 MHz, CD3CN) 0.95 (d, 3H, CH3), 1.66 (m, UH, c-CeHu),
2.75 (m, 2H, CH2), 3.95 (m, 1H, CH-P), 4.20 (q, 2H, OCH2CH3), 5.00 (m, 3H, CH2OOC 
+ PNH), 5.52 (s, 2H, OCH2Ph), 5.87 (d, IH, NHCO), 7.36 (m, 5H, CeHs), 7.50 (d, 2H, 
Ph), 8.15 (d, 2H, Ph); 3lP NMR (101 MHz, CD3CN) 39.2 ppm. FABMS (3-NBA + Li) 
m/e 554.2 (M + Li)+.
Cbz-CyhGly y  [P (S) (OpNb) (OBn)] (19)
It was prepared according to the general procedure (0.22 mmol scale) and purified 
by flash chromatography (silica) using EtOAc-Hexane (1:5) as the eluent. Yield: 19 mg 
(15%). lH NMR (250 MHz, CDC13) 1.55 (m, 11H, c-CftH,,), 4.25 (m, IH, CH-P), 5.12 
(m, 7H, 3CH2 + NH), 7.35 (m, 10H, 2 0 ^ ) ,  7.50 (d, 2H, Ph), 8.18 (d, 2H, Ph); 3IP NMR 
(101 MHz, CDC13) 95.1 ppm. HRMS (ESI/FTMS (CH2C12)) m/e 569.1862 (M + H)+. 
Cbz-CyhGly y  [P (S) (OPNB) O] Ala-OMe (20)
It was prepared according to the general procedure (0.11 mmol scale). Yield: 19 
mg (30%). lH NMR (250 MHz, CD3CN) 1.53 (m, 1 IH, c-Q H ,,), 2.85 (m, 3H, CH3),
4.26 (m, IH, CH-P), 5.28 (m, 5H, 2CH2 + PNH), 5.89 (dd, IH, NHCO), 7.36 (m, 5H, 
CfiHs), 7.45 (d, 2H, Ph), 8.15 (d, 2H, Ph); 3lP NMR (101 MHz, CD3CN) 96.4,97.3 ppm. 
FABMS (3-NBA) m/e 565.2 (M + H)+.
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Chapter 3
Synthesis of a,a-DialkyIated Amino Acid-Rich Peptides 
with Antimicrobial Activity
3.1 Introduction
The classical a-helix and the 3to-helix are the two most prevalent helices found in 
proteins.3' 1*3 3  Whereas the a-helix is characterized by 3.6 residues per turn and a (i, i + 
4), thirteen-membered, hydrogen-bonding pattern, the 3io-helix is distinguished by 3 
residues per turn and a (i, i + 3), ten-membered, hydrogen-bonding configuration. The 
conformational parameters of the two helices are not widely different; however, the 310- 
helix is slightly tighter and more elongated than the a-helix.3' 1*3 2  The 3io-helix is less 
common than the a-helix; it accounts for approximately 1 0  % of all helical structures 
found in proteins.3 3 *33  Nevertheless, structural work conducted on the 3io-heIix suggests 
that it plays a very important biochemical role.33  It is considered to be a protein folding 
intermediate to the a-helical conformation.3 4 3  6 Furthermore, it is believed that protein 
recognition steps could possibly involve facile transitions between a- and 310- 
helices.34,3'7 Therefore, there has been an enormous interest in trying to understand the 
preferences for a- or 3to-helical conformations and the transitions between these two 
states.3-2*3 3 -3'8*3' 10
It is well-established that a-aminoisobutyric acid (Aib), as well as several other a, 
a-dialkylated amino acids, are strong promoters of the 3io-/a-helical conformation.3 8*3 11 
The backbone torsional angles (<|>, \p) (Figure 3.1) of an Aib residue are severely 
restricted, resulting in the pronounced propensity of this residue to favor helical 
structures, even in short peptides.3'8*3 12 Some proteinogenic amino acids, like leucine
71
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and alanine, also promote helicity but not to the extent required for preparation of short 
3io- or a-helical peptides.3' 10
Allowable phi, psi angle pair for Aib (R. R | = CH-0 
-57 °C, -47 °C (right-handed a- or 3io-helix)
57, °C, 47 °C Qeft-handed a- or 3I0-helix)
Figure 3.1 Backbone torsional angles of an Aib residue
The type of helix that an Aib-rich peptide preferentially forms is governed by several 
factors such as main-chain length, Aib content, sequence, and environmental conditions. 
Karle et. al reported that Aib-rich peptides with 5 residues or less give rise to 3io-helices, 
but peptides with ten or more residues form a-heiices.3"12 For medium length peptides (6 - 
10), either an a- or 3io- helix can form, depending mainly on the percentage of Aib’s or 
a,a-amino acids (aaAAs) contained in a peptide. Six residue or longer peptides with 50 
% or more aaAAs are reported to form a 3io-helix while those containing less than 50% 
generally favor an a-helix.3'9 3 ' 12 Basu et al. reported that the location of monosubstituted 
amino acids in Aib-rich peptides also affected the 3t</a-helix equilibrium: the a-helix is 
favored when two monosubstituted amino acids are next to each other, but the 3to-helix, 
when no two monosubstituted amino acids are next to each other.3 9 As far as solvent
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effects, several studies (theoretical and empirical) revealed that Aib-rich peptides favor 
the a-helix in polar media but the 3io-helix in nonpolar media.3"3"5 6,3' 13' 3' 14
Until recently, most studies conducted on the solvent effects on the 3io-/a-helix 
equilibrium were limited to spectroscopic measurements of hydrophobic peptides (e.g., 
oligomers of Aib) in organic solvents or X-ray structure determinations of peptides 
crystallized from organic solvents.3 3 3 '8 3 ' 103' 13' 3' 15 Toniolo et al. reported the first short 
(7-mer) Aib-rich peptide that exhibited its 3i®-helical structure in pure water (Figure 3.2). 
The peptide comprised the extremely water-solubilizing, azacrown-functionalized a- 
amino acid, L-2-amino-3[l-(l,4,7-triazacyclo-nonane)]propanoic add (ATANP) .3 1316 In 
addition, the design and synthesis of short, amphipathic a- and 3io-helices, incorporating 
60% Aib content and the water-solubilizing a,a-disubstituted amino acid, Api (4- 
aminopiperidine-4-carboxylic add), that exhibited their designed structures (Figure 3.2) 
in aqueous media (25 mM SDS) were reported by Yokum et a/ . 3 17 They also reported 
that amphipathic design was foremost in controlling secondary structure (helical 
preference), overriding traditional key factors such as the number of aaAAs and the order 
of the a-amino acids and aaAAs in a sequence. Furthermore, the peptides exihibited 
substantial antibacterial activity.3,18
An amphipathic helix is a protein helix that has opposing polar and non-polar 
faces oriented along its axis.3' 19 Scores of naturally occurring antimicrobial peptides 
contain an amphipathic a-helix as the primary structural motif.330'331 They kill bacteria 
by primarily disrupting the cell membrane. Many studies directed toward understanding 
the structure-activity relationships (SAR) of natural antimicrobial peptides indicate that 
their amphipathic character plays a vital role in their biological activities (peptide
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Also, a reported, general trend exists between the helicity
of an amphipathic peptide and bioactivity. Generally, the higher a peptide's helicity is, 
the higher its bioactivity. However, amphipathic, a-helical peptides with 18 or more 
residues tend to have high cytotoxicity. Short peptides (10-16 residues of varying 







Figure 3.2 Short, water-soluble 3io-helical peptides. The top peptide has 3io-helicity in 
pure water and the bottom peptide (Ipi-10), in aqueous 25 mM SDS.
shown to have comparable antimicrobial activities as longer or native peptides. They
have also exhibited a higher degree of selectivity of bacterial killing over lysis of red
blood cells.3"20' 3^ 2 Conversely, many natural peptide antibiotics, especially those
containing Aib residues, are thought to form 3io-helices.3 23*3 J5  In addition to reports of
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short, amphipathic a-helical peptides with significant antimicrobial activity, there has 
also been a report of short, amphipathic, 3io-helical peptides exhibiting antibacterial 
activity.3'25 Since 3io-helical peptides are about 20% longer than a-helical peptides with 
the same number of residues, amphipathic 3io-helical peptides could possibly retain 
biological activity at shorter peptide lengths than analogous a-helical peptides.
In our work we were interested in the design and efficient synthesis of short, 
amphipathic 3io-helical peptides (Aib-rich) that are capable of exhibiting good 
antimicrobial activity and low cytotoxicity. The general strategy was to shorten the 
amphipathic 10-mer (Ipi-10) in Figure 3.2 to a 9-mer by removing the /'/-terminal Api 
residue. We proposed that removal of this residue would increase the 3io-helicity-and 
therefore bioactivity-of the resulting 9-mer in an aqueous medium due to the removal of 
electrostatic repulsive interactions that may exist between the N-terminus amine and 
charged Api-residue. We observed that the 7-mer peptide (Figure 3.2), which folded into 
a 3 io-helix in pure water,3' u ' 16 had shorter a-amino acid side-chains than the 10-mer 
peptide. Therefore, we decided to expand the scope of our research by investigating the 
effects of further shortening of the length (methylene groups) of the lysine residues in our 
9-mer peptide. We also envisioned an increased 3io-helicity trend with decreased side- 
chain length in our designed peptides. Furthermore, we were interested in the solvent 
(aqueous-organic) effects on the 3io-/a-helix equilibrium on our designed, amphipathic 
3io-helical peptides.
Electronic circular dichroism (CD) is the most widely employed spectroscopic 
technique for monitoring the secondary structure of peptides and proteins as a function of 
solvent.* 27 Both 3io-and a-helical peptides give rise to negative CD bands around 222
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nm (n-wi*) and 207 nm (it->7c* ) .3'23 A positive band around 191 nm (tc-mi*) is also
characteristic of both types of helical peptides, although it is usually much weaker in 3io
helical peptides. The ratio R of the intensity of the negative bands, where R =
[0]n-*«/[9]*-Mi*> is a generally accepted parameter used to distinguish a 3to-helix from an
a-helix. For an a-helix R = 1, but for a 3io helix R = < O.4.3 22
3.2 Results and Discussion
32.1 Peptide Design and Synthesis
The four homologous series of short peptides (9-mers) 3.1-3.4 and their acetylated 
versions 3.5-3.8 listed in Table 3.1 are die novo designed peptides composed of 78% a,a- 
disubstituted amino acids (aaAAs). The sequences of 3.1-3.8 were based on one of the 
peptides (3.9) first described by Yokum et al,317 Peptide 3.1 is actually 3.9 minus the N- 
terminal Api (4-aminopiperidine-4-carboxylic acid) residue. Like 3.9, peptides 3.1-3.8 
were designed to form amphipathic, 3io-helical peptides. The 9-mers 3.1-3.8 contain 
either two lysines or two lysine analogs-omithine, 2 ,4  diaminobutanoic acid (Dab), or 2, 
3 diaminopropanoic acid (Dap)-and 7 achiral aaAAs-six Aib residues and one Api 
residue. The distinction between each peptide, besides acetylation, is the length (# of 
methylene groups) of the side-chains of its a-amino acids (Figure 3.3). In this study we 
primarily investigated, starting with 3.1, how further shortening (main-chain and side- 
chain) of 3.9 would affect the resulting peptide’s secondary structure in various solvent 
media, antimicrobial activity, and cytotoxicity. Furthermore, we hypothesized that 
removal of the positive charge (- Api) at the N-terminus of 3.9 would increase the 
designed amphipathic, 3io-heIicity of the resulting peptide in aqueous media, thereby, 
possibly improving bioactivity due to an overall better peptide-membrane interaction.
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3.6 AcIpiom-9 Ac-Aib-Aib-0 m-Aib-Aib-0 m-Aib-Aib-Api-NH2
3.7 AcIpidab-9 Ac-Aib-Aib-Dab-Aib-Aib-Dab-Aib-Aib-Api-NH2
3.8 AcIpidap-9 Ac-Aib-Aib-Dap-Aib-Aib-Dap-Aib-Aib-Api-NH2
3.9 Ipi- 1 0 H-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2
3.10 Aclpi-10 Ac-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2
The aaAAs were incorporated into 3.1-3.8 to induce a stable, helical, secondary 
structure in the short peptides. The L-lysine or L-lysine-like residues were included to 
induce a right-handed helix (detectable by CD) and were separated well in the middle of 
the sequences (in 4th and 7th position) to have the greatest effect.3 9 As mentioned above 
the peptides were designed to be amphipathic with the charged Api and lysine or lysine­
like residues forming the hydrophilic face and the nonpolar Aib residues forming the 
hydrophobic face. As seen in Figure 3.4 the designed peptides are more amphipathic in 
the 3to-helical representation.
The % 3 io-helix was estimated using the following equation: % 3 io-helix = (100) 
[[01*-rt*/ -21,500], where the minimum for [S]*-** is observed from 205-209 nm.317,3'28






Xxx = Lys (n = 4), Om (n = 3), Dab (n = 2), or Dap (n = 1) R = H, Ac, Api, Ac-Api 
Figure 33  General chemical structure of peptides 3.1*3.10
The CD spectra of H-(Leu-Arg-Leu)g-OH in diphosphatidylcholine liposomes served as 
the model 3io-helix, where = -21,500 deg cm2 dmol' 1 is defined as 100% 3 j o -
helix.3-28 No formal methods have been suggested in literature for the estimation of % 
3io-helicity. For estimation of the % a-helix the following equation was employed: % a- 
helix = -100 ([0]n-*« + 3000) /  33,000, where the minimum for the [0]n_,*» is observed 
from 222-225 nm.3'29
Solid-phase synthetic techniques were employed, using a Milligen 9050 peptide 
synthesizer, in the prepartion of our designed peptides 3.1-3.8 and peptides 3.10*3.12. 
The aaAAs employed in our synthesis were Fmoc-Api(Boc)-OH, Fmoc-Aib-OH, and the 
dimer, Fmoc-Aib-Aib-OH (Figure 3.5). The synthesis of peptides containing multiple 
aaAAs is inherently complicated due to severe steric hindrance caused by 
tetrasubstitution at the a-carbon. Previously, the use of aaAA residues has been limited 
because of the difficulty of coupling or harsh conditions used for their incorporation.3 11 
Carpino’s development of acid fluorides for aaAA couplings provided the first method 
for an efficient, mild synthesis (solution- and solid-phase) of peptides rich in aaAAs.330- 
331 This method was initially employed in the preparation of 3.9 and 3.10,317 upon which 
the design of our targets are partially based, with unsatisfactory yields. We therefore
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attempted the preparation of our first peptide 3.1 by using a reported improved in situ 















Xxx = Lys, Om, Dab, or Dap R = H, Ac
Figure 3.4 The a- and 3io-helicaI wheel diagrams and sequence of peptides 3.1- 3.8










Figure 3 .5 The residues employed in synthesis of peptides 3.1-3.10 
amino acid (Api, Aib, and Lys), 8  equivalents of DIEA, and a Fmoc-PAL-PEG-PS resin 
were employed. However, unsatisfactory yields (2-5%) were also obtained initially with 
this method. From analysis of the Fmoc UV traces, which were used to monitor or 
gauge the efficiency of each coupling step, it was determined that every second Aib was 
not coupling efficiently. Therefore, in an effort to improve the yield of 3.1, every second 
Aib in the sequence was double coupled. Again, no significant improvement in yields 
was observed, even with refluxing at 50 °C.
Our next strategy was to employ the Aib residue as a dimer (Fmoc-Aib-Aib-OH). 
We reasoned that the use of the dimer could at least eliminate or lessen the formation of 
deletion sequences (seen in MALDI of collected HPLC fractions), thus, potentially 
improving the yields of 3.1. Conversely, we recognized that the use of an Aib dimer 
could possibly impose even more steric hindrance. Nevertheless, we prepared (solution- 
phase) Fmoc-Aib-Aib-OH for use in preparation of 3.1 and, eventually, the other peptides 
listed in Table 3.1.
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The dimer, Fmoc-Aib-Aib-OH, was prepared (Scheme 3.1) by using a 
combination of CarpinG’s acid fluoride method330"331 and Bolin’s procedure.333 The 
monomer, Fmoc-Aib-OH, was first treated with cyanuric fluoride to form the amino acid 
fluoride 3. Compound 3 was then reacted with the silylated amino acid 5, which was 
prepared from the reaction of H-Aib-OH 4 and trimethylsilylchloride (TMS-C1), to form 
the dimer 6 , after recrystallization from chloroform/hexane, in 70% yield.
In the first attempted synthesis of 3.1 employing the Aib dimer and application of 
heat (50 °C), we observed, from the Fmoc UV traces, that the first dimer of the sequence 
coupled very poorly but the rest of the Aib dimers coupled very well. However, the 
overall yield (~ 2%) of 3.1 was still low because of the very inefficient coupling of the 
first dimer. We therefore decided to use the Aib monomers, followed by double coupling 
after each one, for the first two Aib’s in the sequence but to continue to use the Aib dimer 
in the rest of the sequence along with refluxing (50 °C). This modification resulted in a 
significant yield increase for 3.1 (20% yield). The dramatic improvement in efficiency of 
preparation of 3.1 can be readily observed in the semi-preparatory HPLC chromatograms 
presented in Figure 3.6 and Figure 3.7. Also, this method was used to prepare the rest of 
the peptides listed in Table 3.1 in yields up to 25%. Analytical HPLC was used to check 
the purity of the peptides (e.g., see Figure 3.8, Figure 3.9, Figure 3.10, Figure 3.11, 
Figure 3.12, and Figure 3.13,).
The good synthetic results of our target 9-mers and 10-mers (Table 3.1) were 
attributed mainly to the incorporation of our Aib dimer. The use of Fmoc-Aib-Aib-OH 
lessened the formation of deletion sequences while increasing the yields of the desired 
sequences. However, as alluded to above, the Aib dimer wasn’t effective, in terms of
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peptide yield, when used for the first two Aibs in the synthesis of the peptides. This was 
attributed to steric factors arising potentially from the coupling of three sequential 
aaAAs (Api + Aib dimer) as well as steric bulkiness from the resin. The sequential 
coupling of Aibs is generally difficult due to inherent strain caused by the additional 
substituent on the a-carbon. Our dimer lessens that complexity significantly because 
instead of being involved in sequential Aib couplings, the dimer is actually coupled to an 
a-amino acid in each peptide’s sequence.
II 1 *  II
RnxT OH + ** Fmoc" ' X F












'  H O
Scheme 3.1 Synthesis of Fmoc-Aib-Aib-OH 6
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Peptide 3.1
Figure 3.6 Semi-pieparatory HPLC profile of crude containing peptide 3.1 before 
improved coupling protocol. HPLC was carried out on a Waters 5 Jim C4 reversed-phase 
column (8  x 100 mm) using a mobile phase of water (0.05 %, v/v, TFA) and acetonitrile 
(0.05 %, v/v, TFA), a gradient of 10-50 % of organic phase over 50 minutes and flow rate 











Figure 3.7 Semi-preparatory HPLC profile of crude containing peptide 3.1 after 
employing improved coupling protocol. HPLC was carried out on a Waters 5 jun C4 
reversed-phase column ( 8  x 100 mm), a gradient of 10-50 % of organic phase over 50 
minutes and flow rate of 1 mL/min. The absorption (UV) was monitored at 222 nm.
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Figure 3.8 Analytical HPLC purity check of isolated 3.1. HPLC was carried out on a 
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
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Figure 3.9 Analytical HPLC purity check of isolated 3.2. HPLC was carried out on a 
Vydac 5-fiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
min. and a flow rate of 1 mL/min.
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Figure 3.10 Analytical HPLC purity check of isolated 3.4. HPLC was carried out on a 
Vydac 5-pM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
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Figure 3.11 Analytical HPLC purity check of isolated 3.6. HPLC was carried out on a 
Vydac 5-pM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
min. and a flow rate of 1 mL/min.
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Figure 3.12 Analytical HPLC purity check of isolated 3.9. HPLC was carried out on a 
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
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Figure 3.13 Analytical HPLC purity check of isolated 3.10. HPLC was carried out on a 
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA) 
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40 
min. and a flow rate of 1 mL/min.
0>
3.10
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3.2.2 Solvent Effects on 3io-/a>HeIix Equilibrium
Peptides 3.1-3.8 were studied in six different solvent systems: 25 mM SDS,
sodium phosphate buffer (pH = 7), CH3CN-TFE (trifluoroethanol) (9:1), and CH3CN- 
H2O [(9:1), (3:1), and (1:1)]. The designed 3io-helical structure of 3.1 (Ipi-9) was most 
evident in 25 mM SDS (Table 3.2). However, since its R value, 0.51, is higher than the 
theoretically accepted value, Ipi-9 is most likely a mixture of both 310 helices (estimated 
23%) and a-helices (estimated 17%). In buffer, Ipi-9 exhibits a more a-helical (R = 0.62, 
16%) structure, although weak, than 310 helical. Also, for Ipi-9, as the percentage (50- 
1 0 0 %)of organic composition increases in the aqueous/organic mixtures, the percent a- 
helicity increases, with the high being 49% in CH3CN-TFE (9:1). This same trend of 
increased a-helicity in the 50-100% aqueous/organic mixtures is also observed with 3.2 
(Ipiom-9) (Table 3.3). However, in SDS micelles, the CD spectrum (R = 0.86) of Ipiom- 
9 is indicative of an a-helical (13%) structure. The designed 3io-helical structure of 
Ipiom-9 is observed most or best in buffer, where its R value is 0.48 and estimated 3io- 
helicity is 24%. The R values and the estimated percent helicity of both Ipiom-9 and 
Ipidab-9 in buffer and 50-75% aqueous/organic mixtures reflect, in general, a significant 
population of both 3io- and a-helical conformations (Table 3.4). Based on the 
characteristic minima (n-wt* and ic-mc*) of helices, Ipidap-9 appears to be helical only in 
CH3CN-H2O (9:1). In this latter solvent system, Ipidap-9 is a-helical with a R value of 
0.72 and 28% helicity. In CH3CN-TFE (9:1), Ipidap-9 appears to be a random coil with a 
minimum centered around 197 nm and a maximum around 215 nm.
As stated in the “Peptide Design” section, the construction of Ipi-9 was based on 
the 3to-helical design of Ipi-10. Indeed, at low temperatures (0-5 °C) in 25 mM SDS, 
Ipi-10 is folded into its designed structure (R = 0.32,25% 3io-helicity) as opposed to Ipi-
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9, which favors an a-helicai structure (R = 0.65, 15% a-helicity) at low temperatures in 
SDS micelles. Solutions of SDS micelles, which possess a negatively charged head 
group and aliphatic tail, are known for induction of ordered structures in peptides and 
proteins. The induction of secondary structure is initiated by the binding of the anionic 
surfactant to the cationic side-chain groups of the peptide; this enhances the binding 
affinity of the peptides to the hydrophobic interior.3-34 Therefore, the observance of the 
designed 3io-helix preferably in Ipi-10 than Ipi-9 may be due to the smaller hydrophilic 
face of Ipi-9; the hydrophilic faces of Ipi-9 and Ipi-10 (R = 0.32) are composed of 3 
residues and 4 residues, respectively. The larger positively charged face of Ipi-10 (+ 5 
overall charge) probably allows for more efficient micelle binding, resulting in better 310- 
helical stabilization than Ipi-9 (+ 4 overall charge) at low temperatures in 25 mM SDS. 
Conversely, at 25 °C in 25 mM SDS, Ipi-10 appears to be a-helical (R = 0.67, 11%) 
while the secondary structure of Ipi-9 appears to be leaning more toward 3to-helical (R = 
0.51, 23% 3 j o  helicity). Furthermore, for Ipi-10, the same trend, 3 t o  to a-helical 
transition as the temperature is increased to 25 °C in SDS, is also seen in the 50-100% 
aqueous/organic mixtures (compare Table 3.5 to Table 3.6).
Of the four 3io-helical designed peptides 3.1-3.4, 3.1 (Ipi-9) possesses the most 
estimated 3io-helical character in SDS (Figure 3.14). Peptides 3.2-33 are more a-helical 
in SDS, which is probably due to incomplete micelle binding. This incomplete binding 
may have caused the solvent environment of 33-33 to have greater aqueous solvent 
characteristics. An a-helix is generally more energetically favored than a 3l0-helix in an 
aqueous environment. This is due to the more favorable interactions of the additional 
exposed carbonyls and amides of an a-helix with water.3 3 hi contrast, 3io-helical
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peptides are generally more stable in a non-polar environment, which arises from the 
additional hydrogen bond formed as compared to the a-helix.33 
Table 3.2 CD data and derived structural parameters for Ipi-9 at 25 °C.
Solvent [0 W * * r o w " R % Helicity
25 mM SDS -5025 -2582 0.51 d
9:1 CH3CN-TFE -19394 -13410 0.69 49(a)
9:1 CH3CN-H2O -17720 -11936 0.67 45(a)
3:1 CH3CN-H2O -7528 -4879 0.64 24(a)
1:1 CH3CN-H2O -8 8 8 -729 0.82 1 1 (a)
Buffer (pH = 7) -3491 -2170 0.62 16(a)
“Units for [0] are deg cm2 dmol'1.
6The minimum for the [0]*-*** band is observed in the range from ~ 205-209 nm. 
The minimum for the [0]*_»*« band is observed in the range from ~ 222-225 nm. 
^The % a-helix is estimated at 17%, and the % 3io-helix is estimated at 23%.
Table 3 3  CD data and derived structural parameters for Ipiom-9 at 25 °C.
Solvent r o w * 6 [0 W " R % Helicity
25 mM SDS -1336 -973 0.72 13(a)
9:1 CH3CN-TFE -12866 -8555 0 .6 6 35(a)
9:1 CH3CN-H2O -4873 -7696 1.5 32(a)
3:1 CH3CN-H2O -3407 -1911 0.56 15(a)
1:1 CH3CN-H2O -2975 -1614 0.54 14(a)
Buffer (pH = 7) -5111 -2474 0.48 d
“Units for [0] are deg cm2 dmol'1.
^The minimum for the [©]*_**• band is observed in the range from ~ 205-209 nm. 
The minimum for the [0]x-*» band is observed in the range from ~ 222-225 nm. 
rfThe % a-helix is estimated at 16%, and the % 3io-helix is estimated at 24%.
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Table 3.4 CD data and derived structural parameters for Ipidab-9 at 25 °C.
Solvent [0 W W R % Helicity
25 mM SDS -955 -583 0.61 1 1 (a)
9:1 CH3CN-TFE -3173 -1990 0.62 15(a)
9:1 CH3CN-H2O -2 0 0 0 -2500 1 .2 16(a)
3:1 CH3CN-H2O -3363 -2179 0.64 16(a)
1:1 CH3CN-H2O -4166 -2637 0.63 17(a)
Buffer (pH = 7) -4115 -2364 0.57 d
"Units for [0] are deg cm2 dmol'1.
The minimum for the [0]*-*» band is observed in the range from ~ 205-209 nm. 
‘The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm. 
‘The % a-helix is estimated at 16%, and the % 3io-helix is estimated at 19%.
Table 3.5 CD data and derived structural parameters for Ipi-10 at 5 °C.
Solvent [0 W ^ r Rc % Helicityc
25 mM SDS -5316 -1750 0.32 25(310)
9:1 CH3CN-TFE -9916 -3145 0.33 45(310)
9:1 CH3CN-H2O -6740 -3605 0.54 e
1:1 CH3CN-H2O -4204 -3118 0.74 1 0  % (a)
"Units for [0] are deg cm2 dmoPT
T he minimum for the [0]x-,** band is observed in the range from ~ 205-209 nm. 
c Data from reference
‘The minimum for the [0]*_,*« band is observed in the range from ~ 222-225 nm. 
‘The % a-helix is estimated at 12%, and the % 3to-helix is estimated at 31%.
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Table 3.6 CD data and derived structural parameters for Ipi-10 at 25 °C.
Solvent fe w * * [0 W * C R % Helicity
25 mM SDS -941 -627 0.67 1 1 (a)
9:1 CH3CN-TFE -14603 -10189 0.70 40(a)
9:1 CH3CN-H2O -7347 -7163 0.97 30(a)
3:1 CH3CN-H2O -4770 -3831 0.80 25(a)
1:1 CH3CN-H2O - 1 0 2 0 -1576 1.5 14(a)
Buffer (pH = 7) -7382 -7190 0.97 31(a)
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]*-*** band is observed in the range from ~ 205-209 nm. 
The minimum for the band is observed in the range from ~ 222-225 nm.
However, Ipiom-9, of the four peptides, exhibited the highest estimated 3io- 
helicity (24%) in aqueous buffer (Figure 3.15). Therefore, shortening the side-chain of 
Ipi-9 to form Ipiom-9 resulted in better 3to-helical stabilization in an aqueous buffer 
medium, although this 3 to helical stabilization wasn’t afforded to Ipiom-9 in 25 mM 
SDS, which may have been due to a host of factors such as ion pairing of the charged 
polar groups with SDS sulfonates or even incomplete micelle binding. Maybe the shorter 
side-chains of Ipiom-9 interacted less favorably than the side-chains of Ipi-9 with the 
hydrophobic region of the SDS micelles. Further shortening of Ipiom-9 to Ipidab-9 
resulted, based on R values, in primarily an a-helix in the 90% organic but a significant 
population of both helical forms in the other solvent systems tested; however, the helices 
were generally much weaker, based on the absolute ellipticity values, than the helices of 
Ipi-9 and Ipiom-9 (Table 3.4 and Figure 3.16). A decrease in absolute ellipticity is often 
observed with a decrease in a peptide’s main-chain.323 In this study, a shortening of a 
peptide’s side-chain also seems to correlate with a decrease in absolute ellipticity.
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Furthermore, this observed weakening of helicity may be caused by the charged amines 
of the shorter side-chains of Ipidab-9 hydrogen-bonding to nearby carbonyls, thereby, 
decreasing the stability of the folded structures by weakening the strength of the 
intramolecular hydrogen-bonds. Similar kinds of bifurcated hydrogen bonds in proteins 
between a helix and water or a side-chain have been reported and analyzed.3' 12
Further shortening of Ipidab-9 to form Ipidap-9 results in further helical 
destabilization in all of the solvent systems except CH3CN-H2O (9:1), in which an a- 
helical (R = 0.72, 28%) structure is observed. Ipidap-9 seems to form a random coil in 
CH3CN-TFE (9:1) (Figure 3.17). Ipidap-9 lacks a well-defined structure in the other 
solvent systems but is not completely random; a blue shift is observed for the 7t->n* 
transition. The observed wavelengths of Ipidap-9’s x-wt* transitions in buffer, CH3CN- 
H2O (1:1), CH3CN-H2O (3:1), and 25 mM SDS were 199 nm, 190 nm, 198 nm, and 195 
nm, respectively. However, the n-»x* transitions in those solvent systems were observed 
around the wavelength ( 2 2 2  nm) expected in a helical peptide.
The terminally-blocked, 3io-helical peptide (7-mer), described by Toniolo et al., 
had a reported R value of 0.36 in buffer (pH = 7,25 °C). In buffer (pH = 7, 25 °C), Ipi-10 
has a R value of 0.97, and Ipiom-9, a R value of 0.48. Therefore, our designed 9-mer, 
Ipiom-9, is more 3i©-helical in neutral buffer than Ipi-10 but less 3jo-helicaI than the 7- 
mer peptide. The 7-mer is composed of 71% aaAAs, and Ipiom-9, 78% aaAAs. 
Further shortening of the main-chain of Ipiom-9 would still result in a significant 
percentage, 75%, of aaAAs. Therefore, the further shortening of the main-chain of 
Ipiom-9, along with the amphipathic design tool, could possibly lead to a 3io-helical 
structure that is even more comparable to the terminally-blocked 7-mer peptide.
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Figure 3.14 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (?) and Ipidap-9 (♦) in 
25 mM SDS.
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Figure 3.15 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (y) and Ipidap-9 (4 ) in 
neutral, aqueous buffer at 25 °C.
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Figure 3.16 CD spectra of Ipi-9 £ ), Ipiom-9 $ ), Ipidab-9 ) and Ipidap-9 ̂ ) in 
CH3 CN-H20  (9:1) at 25 °C.
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Figure 3.17 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (▼) and Ipidap-9 (♦) in 
CH3 CN-TFE (9:1) at 25 °C.
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Temperature dependence of the CD spectra of 3.1-3.4 in buffer and of 3.1-3.2 in 
25 mM SDS were obtained. CD spectra of each peptide were recorded at temperatures in 
10° increments from 30 to 70 °C. In buffer all of the peptides were more a-helical than
310-helical at all temperatures tested (Table 3.7, Table 3.8, Table 3.9, and Table 3.10).
Table 3.7 CD data and derived structural parameters for Ipi-9 in buffer (pH = 
30 to 70 °C.
7) at
Temperature ro w * * [0]n-***fl,C R % Helicity
30 -3584 -2775 0.77 18(a)
40 -1475 -1006 0 .6 8 1 2 (a)
50 -2170 -1544 0.71 14(a)
60 -2047 -1149 0.56 13(a)
70 -1923 -1293 0.67 13(a)
“Units for [0] are deg cm2 dmol1.
*The minimum for the [0]*_«i* band is observed in the range from 205-209 nm. 
T he minimum for the band is observed in the range from 222-225 nm.
Table 3.8 CD data and derived structural parameters for Ipiom-9 in buffer (pH = 7) at 
30 to 70 °C.
Temperature r o w * ’6 [ 9 W V R % Helicity
30 -6269 3694 0.59 2 0 (a)
40 -5082 -3119 0.61 19(a)
50 -2354 -1668 0.71 14(a)
60 -3147 -1902 0.60 15(a)
70 -2871 -1814 0.63 15(a)
“Units for [0] are deg cm2 dmol'1.
T be minimum for the [0]*-** band is observed in the range from -  205-209 nm. 
‘The minimum for the [0]»-«* band is observed in the range from -  222-225 nm.
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Table 3.9 CD data and derived structural parameters for Ipidab-9 in buffer (pH = 7) at
30 to 70 °C.
Temperature [0 ]*-** [8 W W R % Helicity
30 -1143 - 8 6 8 0.76 1 2 (a)
40 -156 -189 1 .2 1 0 (a)
50 -626 -608 0.97 1 1 (a)
60 -549 -500 0.91 1 1 (a)
70 -664
j  _2 j .-1
-487 0.73 1 1 (a)
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]*-** band is observed in the range from ~ 205-209 nm. 
T he minimum for the [0]x-nt* band is observed in the range from ~ 222-225 nm.
The greatest percentage of a-helicity for each peptide was shown at 30 °C. As the 
temperature increased to 70 °C, the general trend observed was weakening of the helicity 
of the peptides, which was indicated graphically by the decreasing intensity of the molar 
eilipticities of the characteristic minima and numerically by the calculated, decreasing 
percent helicity (Figure 3.18, Figure 3.19, Figure 3.20, Figure 3.21). Interestingly, 
Ipidap-9, which didn’t have a well-defined structure in buffer at 25 °C, possessed the two 
minima transition bands characterized by helical peptides at 30-70 °C. In this study, no 
helix-coil transition nor a-helix to 3io-helix transition was observed. Furthermore, data 
obtained by heating and cooling experiments for each peptide were not significantly 
different, which demonstrate the reversibility of the thermal transition from 30 to 70 °C 
in buffer.3"55
There appeared to have been a small a- to 3to-helical transition in 25 mM SDS for 
Ipi-9 in the temperature range of 30 to 70 °C (Table 3.11 and Figure 3.22). This is based
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Table 3.10 CD data and derived structural parameters for Ipidap-9 in buffer (pH = 7) at
30 to 70 °C.
Temperature [ 0 W * [9 W * C R % Helicity
30 -6100 -3793 0.62 20(a)
40 -6375 -3585 0.56 20(a)
50 -3258 -2193 0.67 16(a)
60 -3736 -2106 0.56 15(a)
70 -4348 -2525 0.58 17(a)
“Units for [0] are deg cm2 dmol'1.
^The minimum for the [0]*_«« band is observed in the range from -  205-209 nm. 
“The minimum for the [©]*_*** band is observed in the range from ~ 222-225 nm.
on the percent 3io-helicity and R values of Ipi-9. At 30 °C and 70 °C the R values and 
percent 3io-helicity of Ipi-9 are 0.5, 13% and 0.38, 18%, respectively. For Ipiom-9, the 
percent 3to-helidty (~9%) remains fairly constant over the range of temperatures in 25 
mM SDS; however, there was a noticeable decrease in the R values (Table 3.11 and 
Figure 3.23). At 30 °C and 70 °C the R values of Ipiom-9 were 0.42 and 0.26, 
respectively. Overall, it appears that both Ipi-9 and Ipiom-9 possess their designed 310- 
helical structures in 25 mM SDS at higher temperatures (30 to 70 °C).
Increasing the temperature of a SDS micelle solution generally increases its 
critical micelle concentration (CMC).336 Our studies were performed in 25 mM SDS, 
which is high above its CMC; therefore, the concentration of micelles versus monomer 
surfactants may not have changed significantly with the increase in temperature.
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Figure 3.18 CD spectra of Ipi-9 at 30°C (e),40°C (----- -), 50°C (------ ),
60°C (------ ), 70°C-(------ ) in neutral, aqueous buffer.
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Figure 3.19 CD spectra of Ipiom-9 at 30°C ( e),40°C (■), 50°C (♦), 60°C (▼), 
and 70°C (+) in neutral, aqueous buffer.
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Figure 3 JO CD spectra of Ipidab-9 at 30°C ( ),40°C (------ ), 50°C (------ ),
60°C (------ ), 70°C (------ ) in neutral, aqueous buffer.
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Figure 3.21 CD spectra of Ipidap-9 at 30°C ( ),40°C (-------), 50°C (----
60°C (------ ), 70°C-(------ ) in neutral, aqueous buffer.
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However, the size and shape of the micelles could have possibly changed during the rise
in temperature. Ramesh and Labes337 suggest a spherical to cylindrical to a bilayer
structure as the temperature increases. It has been suggested that the differences in
helical content are possibly due to the relative binding affinity of peptides with SDS
micelles.319 Increasing the temperature of our SDS solution may have modified the
shape or size of the micelles resulting in a more favorable interaction with the peptides.
Table 3.11 CD data and derived structural parameters for Ipi-9 in 25 mM SDS at 
30 to 70 °C.
Temperature [ 0 W ^ R % Helicity
30 -2727
•
-1380 0.50 13 (3,0)
40 -3277 -1548 0.47 15 (3I0)
50 -3258 -1349 0.41 15(3,o)
60 -3731 -1385 0.37 17(3,o)
70 -3813
2 j i-l
-1467 0.38 18 (3, o)
“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-** band is observed in the range from ~ 205-209 nm. 
‘The minimum for the band is observed in the range from ~ 222-225 nm.
A study was also conducted on the effect of the different solvent systems 
described above on the designed 3io-helical acetylated peptides 3.S-3.9. Blocking of the 
N-terminus, as well as the C-terminus, of a designed helical peptide generally adds to its 
stability; it eliminates the fixed-end charges that could cause either destabilization of 
helices or inhibition of formation of helices.338 Stability is also afforded helical peptides 
that are N-acetylated at the N-terminus due to the additional hydrogen bond; the carbonyl 
of the blocking group acts an extra hydrogen bond acceptor.3'16 The first reported
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Table 3.12 CD data and derived structural parameters for Ipiom-9 in 25 mM SDS at
30 to 70 °C.
Temperature [0 ]n-*x*a’C R % Helicity
30 -1941 -812 0.42 9(3,o)
40 -1860 -695 0.37 9 (3,0))
50 -1893 -735 0.38 9(3,o)
60 -1958 -435 0 . 2 2 9(3,o)
70 -1944 -515 0.26 9(3,0)
“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-«* band is observed in the range from ~ 205-209 nm. 
“The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm.
experimental CD spectrum for a right-handed 3,o-helical peptide in TFE was a short, 
hydrophobic, acetylated peptide (Ac-[L-(a-Me)Val]8-OtBu) . 3' 1 Also, the acetylated 
peptide, Ac-Aib-ATANP-(Aib)2-ATANP-(Aib)2-OMe, was the first reported example of 
a short peptide assuming 3io-helical conformation in pure water.3 1 6  Peptide 3.6 
(AcIpiom-9) assumed its designed 3io-helical structure appreciably in 25 mM SDS and 
CH3CN-TFE (9:1). Its R values and percent 3io-helicity was, in SDS, 0.42 and 11%, 
respectively, and 0.24 and 20%, respectively, in CH3CN-TFE (9:1) (Table 3.13; Figure 
3.24; Figure 3.25). Peptide 3.7 (AcIpidab-9) assumed a 3to helical structure in CH3CN- 
TFE (9:1) with a R value of 0.49 and 22% estimated 3io-helicity (Table 3.14), and 
peptide 3.10 assumed a 310-helical structure in 25 mM SDS with a R value of 0.38 and 41 
% 3io-helicity (Table 3.15). For the other acetylated peptides, 3.5 (Table 3.16) and 3.8 
(Table 3.17), mainly a-helices formed in the six solvent systems, particularly in neutral 
buffer (Figure 3.26) and CH3CN-H2O (9:1) (Figure 3.27), employed except for 3.8 in 25 
mM SDS, in which no clear helical or secondary structure was evident.
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Figure 3.22 CD spectra of Ipi-9 at 30°C (▼), 40°C (♦), 50°C (■),60°C ( • )  
and 70°C (+) in 25mM SDS
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Figure 3.23 CD spectra o f Ipiom-9 at 30°C ( ),40°C (------ ), 50°C (------ ),
60°C (------ ), 70°C (------ ) in 25 mM SDS.
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Table 3.13 CD data and derived structural parameters for AcIpiom-9 at 25 °C.
Solvent [ B L / [0 W ftf R % Helicity
25 mM SDS -2432 -1037 0.42 11 (3 to)
9:1 CH3CN-TFE -4287 -1023 0.24 20 (3 to)
9:1 CH3CN-H2O -11606 -11811 1 45(a)
3:1 CH3CN-H2O -3510 -3044 0.85 18(a)
1:1 CH3CN-H2O -2489 -2003 0.80 15(a)
Buffer (pH = 7) -7330 -8145 1 .1 34(a)
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]x-*k« band is observed in the range from ~ 205-209 nm. 
'The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm.
Table 3.14 CD data and derived structural parameters for AcIpidab-9 at 25 °C.
Solvent [0 W w R % Helicity
25 mM SDS -1706 -983 0.57 1 2 (a)
9:1 CH3CN-TFE -4700 -2329 0.49 22(3,o)
9:1 CH3CN-H2O -1513 -2660 1.7 17(a)
3:1 CH3CN-H2O -1600 -1433 0.89 13(a)
1:1 CH3CN-H2O -1303 -1654 1 .2 14(a)
Buffer (pH = 7) -2228 -2451 1 .1 16(a)
“Units for [0] are deg cm2 dmol*1.
T̂he minimum for the [0],_«* band is observed in the range from -  205-209 nm. 
The minimum for the [0]*_*» band is observed in the range from -  222-225 nm
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Table 3.15 CD data and derived structural parameters for Aclpi-10 at 25 °C.
Solvent [0 ]« V 4 te w * " R % Helicity
25 mM SDS -8814 -3362 0.38 41 (310)
9:1 CH3CN-TFE -25375 -19938 0.78 70(a)
9:1 CH3CN-H2O -12701 -13864 1.1 51(a)
3:1 CH3CN-H2O -12240 -12714 I 47(a)
1:1 CH3CN-H2O -9857 -10075 1 40(a)
Buffer (pH = 7) -9794 -9294 0.94 37(a)
“Units for [0] are deg cm2 dmol'1.
T he minimum for the band is observed in the range from ~ 205-209 nm. 
T he minimum for the [0]*-** band is observed in the range from -  222-225 nm.
Table 3.16 CD data and derived structural parameters for AcIpi-9 at 25 °C.
Solvent t e w 1’* R % Helicity
25 mM SDS -4877 -3151 0.64 d
9:1 CH3CN-TFE -19472 -13295 0.68 49(a)
9:1 CH3CN-H2O -18611 -17432 0.93 62(a)
3:1 CH3CN-H2O -9548 -8136 0.85 34(a)
1:1 CH3CN-H2O -8025 -7748 0.96 32(a)
Buffer (pH = 7) -3998 -4277 1.1 22(a)
“Units for [0] are deg cm2 dmol'1.
The minimum for the [0]*_** band is observed in the range from ~ 205-209 nm. 
The minimum for the [0]*-»** band is observed in the range from ~ 222-225 nm. 
The % a-helix is estimated at 19%, and the % 3to-heIix is estimated at 23%.

















180 190 200 210 220 230 240 250
Wavelength (nm)
Figure 3.24 CD spectra of AcIpi-9 (•), AcIpiom-9 (■), AcIpidab-9 (▼) and Aclpidap- 
9 (4) in 25 mM SDS.
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Figure 3.25 CD spectra of AcIpi-9 (•), AcIpiom-9 (■), AcIpidab-9 (▼) and Aclpidap- 
9 (♦) in CH3CN-TFE (9:1) at 25°C.
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Figure 3.26 CD spectra of AcIpi-9 (■), AcIpiom-9 (•), AcIpidab-9 (♦) and Aclpidap- 
9 (▼) in buffer.
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Figure 3.27 CD spectra of AcIpi-9 (+), AcIpiom-9 (•), AcIpidab-9 (■), 
AcIpidap-9 (▼) in CH3C N -H p (9:1) at 25°C.
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Table 3.17 CD data and derived structural parameters for AcIpidap-9 at 25 °C.
Solvent [ 0 U 4i te w * ' R % Helicity
9:1 CH3CN-TFE -1898 -1618 0.85 14(a)
9:1 CH3CN-H20 -5963 -7554 1 .2 32(a)
3:1 CH3CN-H2O -4017 -3188 0.79 19(a)
1:1 CH3CN-H2O -6008 -4980 0.82 24(a)
Buffer (pH = 7) -5895 -6515 0.9 29(a)
“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-»x* band is observed in the range from ~ 205-209 nm. 
cThe minimum for the [0]*-»x« band is observed in the range from ~ 222-225 nm.
The helicity of AcIpi-9 and AcIpiom-9 was measured in buffer at three different 
pH’s, 2,4, and 7 (Table 3.18 and Table 3.19). Based on the R values (0.87-1.1) of both 
peptides, a-helicity is predominantly observed at all tested pH’s. The most stable a- 
helical structure was observed for AcIpiom-9 at pH 4. For both acetylated peptides the 
weakest a-helical structure was observed at pH 2 (Figure 3.28 and Figure 3.29). The 
more acidic medium may have interfered with the helices’ intramolecular hydrogen 
bonding pattern.
In our study, we observed an average increase in stability (based on general 
increase in ellipticity) with the acetylated peptides vs. the non-acetylated peptides. Also, 
our actual design (3io-helical) of the peptides were observed best with the acetylated 
peptides, specifically, AcIpiom-9, AcIpidab-9, and Aclpi-10 in either or both 25 mM 
SDS and CH3CN-TFE (9:1) (Figure 3.12 and Figure 3.13). Particularly noteworthy are 
the differences in CD data obtained for Ipiom-9 and its acetylated version, AcIpiom-9.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
115
The designed, 3to-helical structure of Ipiom-9 was observed best in buffer, where its R 
value is 0.48. However, AcIpiom-9 was better stabilized (based on molar ellipticity) as 
an a-helix in buffer, where its R value is 1.1. The R values of Ipiom-9 in 25 mM SDS (R 
= 0.72) and in CH3CN-TFE (9:1, R = 0.66) indicate that Ipiom-9 exhibits more a-helical 
than 3io-helical structures in these solvent systems. In contrast, the R values of Aclpiom- 
9 in 25 mM SDS (R = 0.42) and in CH3CN-TFE (9:1, R = 0.24) indicate that AcIpiom-9 
folded appreciably into its designed, 310-helical structure under these solvent conditions. 
Table 3.18 CD data and derived structural parameters for AcIpi-9 at 25 °C.
PH [ 0 W 4i [ e w ^ R % Helicity
2 -1873 -1722 0.92 14(a)
4 -2619 -2474 1 17(a)
7 -3998 -4277 1.1 2 2 (a)
“Units for [0] are deg cm2 dmol'1.
^The minimum for the [0]*-** band is observed in the range from 205-209 nm. 
cThe minimum for the [0]*-*** band is observed in the range from 222-225 nm.
Table 3.19 CD data and derived structural parameters for AcIpiom-9 at 25 °C.
PH [ 0 W * [ 0 W ac R % Helicity
2 -4268 -3714 0.87 2 0 (a)
4 -12431 -11282 0.91 43(a)
7 -7330 -8145 1 .1 34(a)
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [©]*-,*• band is observed in the range from ~ 205-209 nm. 
cThe minimum for the [0]*_«* band is observed in the range from ~ 222-225 nm.







190 200 210 220 230 240 250
Wavelength (nm)
Figure 3.28 CD spectra of AcIpi-9 in buffer at pH 7 ( •), pH 4 (■) and pH 2(t )
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Figure 3.29 CD spectra of AcIpiom-9 in buffer at pH 7 ( • ) , pH 4 (■) and pH 2(r)
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The 3io-helical design of our peptides were in accord with the general factors 
(e.g., helix length, number of Aib’s, position of a-amino acids) that favor 3io-helix 
formation, although a-helices were observed for most of the peptides under the six 
solvent conditions. The amphipathic design tool, undoubtedly, played a major role in the 
3io-helices considerably forming in the above, acetylated peptides, especially in the SDS 
micelle media. The length of the side-chains may have also been a factor, particularly for 
AcIpiom-9. The shortening of AcIpi-9 to AcIpiom-9 led to R values, in 25 mM SDS and 
CH3CN-TFE (9:1), that were more indicated of a 3io-helix. However, further shortening 
of the side-chains of AcIpiom-9 to AcIpidab-9 and AcIpidap-9 led to R values that were 
increasingly above the accepted value (R = < 0.4). Furthermore, the extra hydrogen bond 
and slight increase in hydrophobicity in the acetylated peptides may have resulted in the 
increased propensity of 3.6-3.7 to fold into a 310-helix in 100 % organic media.
3.2.3 Bioactivity of Designed Peptides
Many natural antimicrobial peptides of greatly differing sequences have been 
isolated with amphipathic, helical domains as a consistent structural feature.3'20'3'21 Also, 
scores of de novo peptides that comprise only a putative amphipathic helix have activity 
comparable to or greater than that of natural peptide antibiotics.330,3'22 As discussed in 
the previous section, our peptides were designed to be amphipathic, like natural 
antimicrobial peptide, as well as 3to-helical. Amphipathic peptides with 18 or more 
residues could possess high cytotoxicity.339 It’s been reported that by simply reducing 
the length of peptides to 14 residues decrease cytotoxicity while retaining much of the 
antimicrobial activity.330,322 Peptides 3.1-3.8 were prepared to test the hypothesis that 
retention of biological activity and lowering of cytotoxicity could be achieved by further
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shortening (main and side-chains) of the 10-mer peptide, Ipi-10. The secondary structure 
of the peptides in the model membrane, SDS, was correlated with their biological 
activity.
The MIC’s (minimum inhibitory concentration) for the peptides tested against 
Escherichia coli and Staphylococcus aureus are summarized in Table 3.20. E. coli is a 
Gram-negative bacterium, and S. aureus is a Gram-positive bacterium. The distinction 
between Gram-negative and Gram-positive bacteria is based on the differential staining 
procedure, Gram Stain. Gram-negative bacteria stains red, but Gram-positive, purple. 
This difference in reaction to the Gram Stain is due primarily to the differences in the cell 
wall structure of Gram-negative and Gram-positive bacteria.3'40 The cell wall of a Gram- 
negative bacteria is multilayered; it is comprised of thin layer of peptidoglycan (layer 
composed of N-acetylglucosamine, N-acetylmuramic acid, and a few amino acids) and an 
outer membrane composed of lipopolysaccharaide, lipoprotein, and other complex 
macromolecules. The cell wall of Gram-positive bacteria, on the other hand, consists 
chiefly of a thick layer of peptidoglycan; it lacks the outer membrane present in Gram- 
negative cells.3 40
Peptide 3.1 (Ipi-9) inhibits the growth of E. coli at a minimum concentration of 
140 pM; it is about 3 times less active than 3.2 (Ipiom-9). Ipidab-9 (33) inhibits E. Coli 
at approximately 149 pM, which is comparable to 3.1. Ipidap-9 (3.4), with a MIC greater 
than 300 pM, was the least active toward E. coli. Of the acetylated peptides 33-3.8, 
AcIpi-9 (33), with a MIC of 134 pM, exhibited the best activity against E. coli. None of 
the peptides had particularly good inhibitory activity against 5. aureus.
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Antimicrobial peptides kill bacteria by disrupting the cell membrane.3' 19' 3'20 It’s 
been reported that the CD spectra of peptides in micelles suggest a structure/function 
relationship for the bioactive peptides.3^ 0 SDS has an aliphatic tail and a negatively 
charged head group (sulfate). The micelles that SDS forms partially emulate the 
amphipathic environment of membranes. The anionic head groups provide the initial 
electrostatic interactions (with cationic side groups of peptides) needed and enhances the 
binding affinity of peptides to the non-polar interior, thereby, inducing an intrinsic, 
ordered structure. Because Ipi-9, of the four, non-acetylated designed peptides, possesses 
the most amphipathic, 3io-helical structure in SDS, it was expected to be the most active 
against the bacteria; however, Ipiom-9 was the most active. Ipiom-9 did, however, have 
the highest, of the four peptides in all the tested six solvent systems, percentage of 
amphipathic, 3io-helicity in buffer. The order of activity of Ipidab-9 and Ipidap-9, third 
and fourth, respectively, was expected. Ipidab-9 had 19% amphipathic, 3io helicity in 
buffer but very little estimated 3io helicity in SDS. Ipidap-9, on the other hand, lacked a 
well-defined structure in all of the solvent systems tested except the 1 0 0 % organic 
solvent system, CH3CN:TFE (9:1), in which a-helicity was mainly observed. Overall, 
the shortening of Ipi-10 (MIC, 7.7 pM) to make 3.1-33 resulted in diminished, but 
modest activity, against E. coli and no improvement in activity against S. aureus.
Aclpi-10 inhibits E. coli at approximately 7.4 pM; it also exhibited 41% 3io 
helicity in SDS with a R value of 0.38. Shortening of Aclpi-10 to AcIpi-9 resulted in 
reduced activity. However, of the designed acetylated peptides (33-3.8), activity against 
E. coli was only observed for AcIpi-9 (33); it also had the highest estimated percent of 
amphipathic, 3io helicity in 25 mM SDS. Practically no activity against 5. aureus was
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observed for any of the peptides. This may have been due in part to the much thicker cell 
wall (peptidoglycan) S. aureus possesses compared to E. coli. Although E. coli has a 
very thin peptidoglycan, it also has, as mentioned earlier, an additional outer membrane 
not present in S. aureus. However, the outer membrane is relatively permeable to small 
molecules.3'40
Overall, the shortening of the 10-mers, by removing the N-terminus, positively 
charged residue (Api) resulted in reduced 3io-helicity as well as diminished antimicrobial 
activity against E. coli. The larger polar face associated with the non-acetylated 10-mer 
(Ipi-10), compared to the non-acetylated 9-mers, apparently has better peptide-membrane 
interactions in SDS and E. coli. Seemingly, only small, if any, repulsive forces between 
the charged Api residue and the N-terminal amine of the non-acetylated 10-mer exist. In 
any case, elimination of the adjacent charges, by removing the N-terminus Api, doesn’t 
apparently improve helicity or bioactivity. However, acetylation of the 10-mer does 
improve 3io-helicity and bioactivity. Therefore, the larger polar face of the 10-mer 
evidently overcomes any unfavorable like charge-charge effects.
The activity of our peptides against intracellular pathogens, like brucella, was not 
tested; however, their degree of toxicity to normal murine macrophages was examined. 
Macrophages are large white blood cells that ingest foreign particles and infectious 
microorganism by phagocytosis. Table 3.21 shows normal murine macrophage survival 
versus peptide concentration for the peptides 3.1*3.10. Cell death was indicated by the 
enclosure of a trypan blue dye within a cell. Normal untreated murine macrophages have 
a survival rate of ~ 90%. No cytolytic effects were observed for Ipi-10; however, 
shortening it to the 9-mer peptides didn’t lead to any significant cytotoxicity at
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concentrations < 100 pM. Ipiom-9 wasn’t significantly toxic up to the maximum 
concentration o f200 pM. However, 3.1 and 33-3.4 were slightly toxic at 200 pM. None 
of the tested acetylated peptides, based on the presence of a very few to zero blue cells, 
exhibited any significant cytotoxicity.
It is generally accepted that antimicrobial peptides selectively inhibit and kill 
bacteria ova: mammalian cells due to differences in their membranes.3,20,3'41 The exterior 
membranes of mammalian cells are neutral, but bacteria cell exterior membranes are 
negatively charged. Because antimicrobial peptides are positively charged, they might 
preferentially bind to bacteria over mammalian cells. In a previous study,'3-17J-26 the 
highest or optimum peptide dose, which was the maximum nontoxic to very slightly toxic 
dose, that showed > 70% macrophage survival was used as the starting dosage to 
determine if infected macrophages were selectively destroyed relative to non-infected 
macrophages; the average dose used in this study was 10 pM for amphipathic peptides of 
length 10-14 residues. For our 9-mer peptides, a starting dose as high as 200 pM could 
possibly be employed without significant toxicity to the normal macrophages.
The acetylated peptides showed very little cytotoxicity compared to non-acetylated 
peptides. It’s desirable that this be translated into greater selectivity with good 
bioactivity for the acetylated peptides. It has been reported in other similar systems that 
short Aib-rich peptides (11-14 residues, acetylated and non-acetylated) kill infected 
macrophages significantly better than non-infected macrophages in vitro?26 However, 
the acetylated peptides tended to be less effective than its respective non-acetylated 
versions at killing infected macrophages; this was especially observed, for these other 
systems, in vivo. For this above study, the acetylated peptides generally had less than
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good activity against intracellular pathogens in vivo. iV-terminus acetylation decreases 
the overall charge of a peptide while increasing the hydrophobidty, which may lessen the 
amount of peptide actually making it to the infected macrophages present in the spleen 
(in vrvo study). It was hoped that our water-soluble, acetylated and non-acetylated 9- 
mers could overcome possible transport problems in vivo. Also, since our peptides are 
not very significantly toxic at concentrations as high as 200 pM, it is hoped that this 
Table 3.20 Peptide antibacterial activity0 and percent helicity
Peptide E. Coli S. aureus % Helicity
3.1 Ipi-9 140 >281 23,* 16c
3.2 Ipiom-9 36 >290 6 ,* 24c
3.3 Ipidab-9 149 >300 4,* 19c
3.4 Ipidap-9 >300 >300 d
3.5 AcIpi-9 134 >268 23*
3.6 AcIpiom-9 >277 >277 1 1*
3.7 AcIpidab-9 >285 >285 8 *
3.8 AcIpidap-9 >295 >295 e
3.9 Ipi-10 7.7 >247 25f
3.10 Aclpi-10 7.4 >237 41*
0 These MIC (in pM) are corrected for the actual peptide concentration using quantitative 
amino acid analysis.
* % 3io-helicity in 25 mM SDS at 25 °C
c % 3io-helicity in buffer (pH = 7) at 25. °C
d Peptide 3.4 lacks well-defined structure in 25 mM SDS and neutral buffer.
* Peptide 3.8 lacks well-defined structure in 25 mM SDS. 
f % 3io-helicity in 25 mM SDS at 5 °C; it’s only 5 % at 25 °C.
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correlates with great selectively of bacterial killing over normal mammalian cells, which 
would have to be determined via in vivo and in vitro testings.
Table 3.21 Direct peptide toxicity effects on murine peritoneal macrophages
Peptide 200 pM 100 pM 50 pM 10 pM
3.1 Ipi-9 20 % Dead 95 % Viable 95 % Viable 95 % Viable
3.2 Ipiom-9 90 % Viable 90 % Viable 95 % Viable 95 % Viable
3.3 Ipidab-9 20 % Dead No Effect No Effect No Effect
3.4 Ipidap-9 20 % Dead 95 % Viable 95 % Viable 95 % Viable
3.5 AcIpi-9 No Effect No Effect No Effect No Effect
3.6 AcIpiom-9 Granular 
Appearance 
Very few blue 







cells present, but 




No blue ceils 
present. 95- 
1 0 0 % 
Viability
3.8 AcIpidap-9 Granular 
appearance. 
Very few blue 






95 % Viability 95%
Viability
3.9 Ipi-10 Fewer cells but 
no lytic effects






3.10 Aclpi-10 No Effect No Effect No Effect No Effect
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33 Conclusions
Peptides 3.1-3.10, which are rich in aaAAs ( 6  Aibs and 1 Api), were successfully 
prepared using solid-phase synthethic techniques. The in situ coupling reagent, PyAOP, 
was employed in our synthesis. The overall yields of the peptides were significantly 
improved when the dimer, Fmoc-Aib-Aib-OH, was used in the synthesis; however, the 
monomer, Aib, had to be employed, along with double coupling, for the first two Aibs in 
each peptide's sequence.
Peptides 3.1-3.8, whose main-chains were based on the previously described Ipi- 
10 (3.9), were designed to be amphipathic, 3io-helical peptides. The solvents effects on 
each peptide’s 3io-/a-helix equilibrium were measured in aqueous buffer, 25 mM SDS, 
and 50-100 % aqueous/organic solvent mixtures. For the non-acetylated peptides 3.1-33, 
significant populations of both a-and 3io-helices were observed in all of the solvent 
systems tested. Ipidap-9, which was composed of the shortest a-amino acid side-chains, 
was helical (mainly a-helix) only in the 90% organic solvent mixture. The amphipathic, 
310-helical design was observed best, of peptides 3.1-3.4, for 3.2 (Ipiom-9, R = 0.48) in a 
neutral, aqueous buffer at 25 °C. We found that Ipi-10, which is apparently 3io-helical (R 
= 0.32, 25% helicity) at low temperatures (0-5 °C) in 25 mM SDS and 100% organic 
solution (CH3CN-TFE, (9:1)), is more a-helical at 25 °C in these solvent systems as well 
as under the other solvent conditions it was measured in. This wasn’t a trend or tendency 
observed in the other peptides. However, the shortening of Ipi-10 to Ipi-9 did result in 
better 3io-helical stabilization in 25 mM SDS at 25 °C.
Based on the absolute ellipticity values, a general decrease in stability was 
observed for the peptides in buffer upon heating to 70 °C. We found that the thermal
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transition of each peptide was appreciably reversible. An isodichroic point was not 
observed during the temperature or solvent studies, which indicates that these are not 
simple two-state equilibria, but complex equilibria involving three or more folding 
intermediates.
The 310-helical, amphipathic design, based on R values, was observed best for the 
acetylated peptides, specifically 3.6 (Aclpiom) and 3.10 (Aclpi-10). Peptide 3.6 folded 
appreciably into a 3io-helix in 25 mM SDS and CH3CN-TFE (9:1) and peptide 3.10, in 25 
mM SDS. AcIpidab-9 also folded considerably into a 3io-helix in CH3CN-TFE (9:1). In 
buffer, all of the acetylated peptides (R =1) folded mainly into an a-helix.
The antimicrobial activity of our designed peptides was tested against E. coli and 
S. aureus. The shortening of Ipi-10 to 3.1-3.4 resulted in diminished but modest activity 
against E. coli. Of the non-acetylated peptides 3.1-3.4, 3.2 (Ipiom-9), which had the 
highest percent 3io-helicity in neutral buffer, had the best activity against E. coli. Aclpi- 
9, which had the highest estimated 3to-helicity in 25 mM SDS, was the only acetylated 
peptide of 3.S-3.8 to exhibit any activity against E. coli. Of all ten of the peptides, 3.10 
(Aclpi-10), which displayed a R value of 0.38 and 41% 3io-helicity in SDS micelles, had 
the best activity against E.coli. Practically no activity against S. aureus was observed for 
any of the peptides.
The shortening of Ipi-10 to the 9-mer peptides did not lead to any significant 
cytotoxicity in the concentration range of 10-100 uM. Peptides 3.1 and 3.3 were slightly 
toxic at 200 uM. None of the tested acetylated peptides exhibited any significant 
cytotoxicity. This may bode well for the potential selectivity of these peptides for Iyses 
of infected/activated macrophages over non-infected/non-activated macrophages.3' 18




Peptides 3.1-3.10 were synthesized via solid-phase peptide synthesis using a 
Milligen 9050 peptide synthesizer on a PAL-PEG-PS (0.24 nunol/g) solid support. The 
peptides were prepared on a 0.24 mmol scale using the Fmoc-amino acids (0.96 mmol, 4 
equiv.), preformed Fmoc-Aib-Aib-OH (0.96 mmol, 4 equiv.), PyAOP (0.96 mmol, 4 
equiv.), DIE A (1.92 mmol, 8  equiv.), 1.2 h recycling time, and a jacket temperature of 
50 °C. The monomer, Fmoc-Aib-OH, was employed only in the coupling of the first two 
Aibs in the peptide sequences. A double coupling was performed after each Fmoc-Aib- 
OH. A deblocking solution of 2% piperidine/2% l,8-diazobicyclo[4.5.0]undec-7-ene 
(DBU) in DMF was used for Fmoc removal. Peptides 3.1-3.4 and 3.9 were acetylated on 
the solid support (0.12 mmol) by treatment with a 0.2 M solution of acetic anhydride in a 
0.28 M solution of DIEA in DMF for 3 hours.
The peptides were simultaneously cleaved from the resin and side-chain 
deprotected using the following cleavage cocktail: 94% trifluoroacetic acid (TFA), 5% 
water, and 1% triisopropylsilane (TIPS). The resulting acidic solution was diluted with 
30% acetic acid and lyophilized. The crude peptides were purified by reverse-phase 
preparative HPLC on a Waters 15 pM DeltaPak C-4 column using a mobile phase of 
water (0.05%, v/v, TFA) and acetonitrile (0.05%, v/v, TFA) and running a gradient of 
10% to 50% of the organic phase over 1 hour, the absorption was monitored at 222 nm. 
Purities of the peptides were checked on a Vydac 5 pM Cig column running a similar 
mobile phase gradient and monitoring at 222 nm. The molecular weight of each purified
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was prepared from piperidine-4-spiro-5'-hydantoin according to a procedure described in
reference 3.38. To a vigorously stirring suspension of W W ^-tris-tert-
butyloxycarbonyl-8,10-dioxo-4,7,9-triaza-spiro[5,4]cyclodecane (33 g, 71 mmol) in THF
(300 ml,) was added 2 N KOH (300 mL). After stirring for 18 hours, the two-layer clear
solution was poured into a separatory funnel and then the aqueous layer was drained into
Table 3.22 Characterization of Peptides 3.1-3.10
Peptide tR(min.)a Calculated Mass MALDI®
Ipi-9 2 2 .6 910.16 910.99 (M + H)+
Ipiom-9 21.9 882.11 883.67 (M + H)+
Ipidab-9 2 1 .8 854.06 854.25 (M)+
Ipidap-9 2 1 .6 826.01 849.24 (M + Na)+
AcIpi-9 29.4 952.21 953.21 (M + H)+
AcIpiom-9 29.1 924.15 925.47 (M +H)+
AcIpidab-9 29.0 896.10 897.16 (M + H)+
AcIpidap-9 28.5 868.05 869.01 (M. + H)+
Ipi-10 26.2 1036.32 1037.38 (M + H f
Aclpi-10 32.5 1078.36 1078.74 (M + H)+
aReverse-phase HPLC carried out on a C4 column ( 8  x 100 mm) using a mobile phase of 
H2O (0.05% TFA) and CH3CN (0.05% TFA), gradient of 10 to 50% organic phase over 
lh, and a flow rate of 1 mL/min.
*CCA matrix (CH3CN-H20).
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a round bottom flask. Residual THF was removed by rotary evaporation. The aqueous 
layer was acidified to pH 7 with 2 N HC1. The resultant white precipitate was filtered 
and dried in vacuo to yield l-tert-butyloxycarbonyl-4-amino-piperidine-4-carboxylic 
acid. Yield: 15 g (8 8 %). ‘H NMR (250 MHz, CD3SOCD3) 8  1.42 (s, 9 H) 1.90 (m, 4 H), 
3.58 (m, 4 H).
According to Bolin’s procedure,333 under argon, anhydrous methylene chloride 
(150 mL) and DIEA (9.14 mL, 52.4 mmol) was syringed into a flask containing 1-tert- 
butyIoxycarbonyl-4-amino-piperidine-4-carboxylic acid (5.12 g, 20.9 mmol). The 
reaction mixture stirred for 15 minutes at room temperature. Chlorotrimethylsilane 
(TMS-C1) (5.32 g, 41.9 mmol) was then added dropwise , and the solution was heated to 
reflux for 3 hours. After cooling in an ice bath, 9-fluorenylmethyl chloroformate (5.45 g,
21.1 mmol) was added in one portion. The solution was stirred in the ice bath for 20 
minutes and for 3 hours at room temperature. The solvent was evaporated, and the 
product was distributed between Et2 0  (70 mL) and 2.5% Na2CC>3 (300 mL). The 
aqueous layer was separated and washed with additional portions of Et2 0  (2 x 30 mL). 
Residual Et2 0  was removed from the aqueous layer by rotary evaporation and acidified 
to pH 2 in an ice bath using 2 N HC1. The precipitated free acid was extracted with 
EtOAc (100 mL) and additional portions of EtOAc (2 x 60 mL). The combined EtOAc 
fractions were dried over MgSC>4 and filtered. The solvent was removed by rotary 
evaporation, and the resulting yellow solid was dried in vacuo. Yield: 9 g (93%). *H 
NMR (250 MHz, CD3OD) 8  1.40 (s, 9H), 1.75 (m, 2H), 1.96 (m, 2H), 3.04 (m, 2H), 3.76 
(m, 2H), 4.37 (m, 3H), 7.25 (t, 2H), 7.30 (t, 2H), 7.70 (d, 2H), 7.90 (d, 2H). FABMS 
(NBA) m/e 465.3 (M -  H)\
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3.43 A-(9-FluorenylmethoxycarbonyI)aminoisobutyric acid fluoride [Fmoc-Aib-F]
Under argon, Fmoc-Aib-OH (10 g, 30 mmol) was suspended in CH2CI2 (100 mL) 
followed by the addition of pyridine (2.4 mL, 30 mmol) and cyanuric fluoride (5.1 mL, 
61 mmol). The reaction mixture stirred at room temperature for 24 hours, and then it was 
diluted with CH2CI2 (150 mL), poured onto ice-water, and filtered. The organic layer 
was extracted with ice water (2 x 200 mL), dried over MgS04, and evaporated in vacuo 
to yield the acid fluoride as a pink solid. The product was recrystallized from the solvent 
pair, CH2Cl2/hexane. Yield: 8  g (82%). ‘H NMR (250 MHz, CDCI3) 6  1.45 (s, 6 H), 4.25 
(t, 1H), 4.46 (d, 2H), 7.42 (m, 5H), 7.78 (d, 2H), 7.95 (d, 2H).
3.4.4 Fmoc-Aib-Aib-OH
a-Aminoisobutyric acid (3.01 g, 29.2 mmol) was placed in a flask equipped with 
a condenser, heating mantle, and an argon inlet. Anhydrous CH2CI2 (70 mL) was 
syringed into the reaction vessel followed by the addition of TMS-C1 (7.4 mL, 58.4 
mmol). The mixture was refluxed for 2 hours and then cooled in an ice bath. DIE A 
(9.17 mL, 52.6 mmol) and Fmoc-Aib-F (6.37 g, 19.4 mmol) were added in succession. 
The reaction mixture was stirred with cooling for 20 minutes and then warmed to room 
temperature for 2 hours. The solvent was evaporated, and the resulting residue was 
distributed between Et2 0  (160 mL) and 2.5% NaHCC>3 (210 mL). The aqueous layer was 
extracted with 2 x 50 mL of Et2 0 . The aqueous layer was then acidified to pH 2 with 1 N 
HC1 and extracted with EtOAc (3 x 80 mL). The combined EtOAc fractions were then 
dried over Na2S0 4, filtered, concentrated, and dried in vacuo. The final product was 
recrystallized from the solvent pair, CHCls/hexane. Yield: 5.5 g (70%). *H NMR (250 
MHz, CD3SOCD3) 8  1.33 (s, 12H), 4.25 (t, 1H), 4.4 (d, 2H), 7.32 (m, 4H), 7.56 (d, 2H),
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7.83 (d, 2H), 12.24 (bs, 1H). MALDI (CCA) 411.34 (M + H)+. Analysis calculated for 
C23H26N2 0 5 : C, 67.32; H, 6.34; N, 6.83; Found: C, 67.51; H, 6.39; N, 6.77.
3.4.5 Amino Add Analysis
The concentrations of the Peptides (3.2-3.10) were determined by quantitative 
amino acid analysis. Peptide samples containing a norleucine standard were hydrolyzed 
in 6  N HCI and 0.1% phenol for 24 h at 110 °C. This was followed by sodium cation 
exchange chromatography at 65 °C and post-column derivatization with ninhydrin at 
130 °C. The peptide contents of lyophilized powders were between 67% and 80% 
peptide by weight.
3.4.6 Circular Dichroism Measurements
Circular dichroism measurements were performed on a (+)-camphor sulfonic acid
calibrated Aviv 60DS spectropolarimeter at room temperature (except where noted). The
measurements were recorded over a 250-180 range using a quartz cell of 0.1 cm path
length, 1 nm bandwidth, 10 nm/min scan speed, and a 5 second time constant. Baseline
corrections were performed by subtracting each sample spectrum from its respective,
acquired background spectrum. Three repetitive scans were recorded and averaged to
improve the signal to noise ratio. Ellipticity is reported as the mean residue ellipticity [6 ]
>
in units of deg cm2 dm'1, and it’s derived from the formula, [0] = [0]obs (MRW/10/c), 
where [0]obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the peptide (molecular weight divided by the number of peptide 
bonds), c is the concentration (mg/mL) of the sample, and I is the optical path length (cm) 
of the cell.
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CD spectra of all peptides in this study were acquired in solvent systems ranging 
from 100% organic to 100% aqueous (0% organic). Final peptide concentrations of 0.2 
mM were used for the experiments. The peptides were dissolved in acetonitrile for 
spectra taken in 9:1 CHbCNrTFE and 10 mM phosphate buffer (pH 7) for spectra taken in 
SDS. The 10 mM phosphate buffer (pH 7) was also used as the aqueous component in 
the aqueous/organic experiments (CH3CN/H2O).
3.4.7 Minimum Inhibitory Concentration Assays
The MIC of peptides was determined against E. Coli American type culture 
collection (ATCC) 25922 and S. aureus ATCC 25723; they were employed as 
representative Gram-positive and Gram-negative bacteria, respectively. Bacterial 
cultures were grown to midlog phase in nutrient broth and were standardized to a 
McFarland turbidity tube before dilution. Peptide 1:2 serial dilutions were prepared from 
512 pg/mL stock solutions to provide a range of peptide concentrations (256-2 pg/mL) in 
the culture media. 50 pL of the desired peptide solution was added to a sterile well 
containing 50 pL of 5 x 104 cells. The MIC is the lowest peptide concentration that 
prevents the growth of the cells as evidenced by the absence of turbidty after four hours. 
The MIC values are reported as the median assay value for at least three experiments.
3.4.8 Macrophage Assays
The peritoneal macrophages of the ten-week old BALB/c mice had to be extracted 
before toxicity studies with peptides. Briefly, following euthanasia using halothane, the 
cells were harvested by lavage from the peritoneal cavity of the mice using 8  mL of 
RPMI 1640 (Sigma) + 10% fetal calf serum (FCS) and Pen-Strep (Penicillin and 
Streptomycin). The cells were cultured in 96 well plates at a concentration of 5 x 10s
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cells per well in 200 fiL of RPMI1640 + 10% FCS at 37 °C in 5% CO2. The cells were 
allowed to adhere overnight. The cell cultures were enriched for macrophages by 
washing away non-adherent cells, and then 2 0 0  pL of fresh media was added to the 
cultures.
For the toxicity studies, normal macrophage cultures were treated with 0 to 200 
jiM of the test peptide. The peptides were incubated with the cells for 60 minutes at 37 
°C in 5% CO2. The cells were washed 3 times with PBS (phosphate buffered saline) + 
10% FCS to remove any residual peptide. Peptide treated cells were stained with 0.04% 
trypan blue in RPMI 1640 + 10% FCS and Pen-Strep. About 100 to 200 cells per well 
were counted using a hemocytometer and an inverted light microscope. Five wells were 
analyzed per peptide concentration; the number of blue stained cells was recorded. The 
enclosure of trypan blue dye within a cell is indicative of cell death. The percent survival 
was calculated by subtracting the number of blue cell from the total cells and normalized. 
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Chapter 4 
Summary and Future Studies
This dissertation focused on the synthesis and characterization of compounds 
from two classes of peptide analogs, phosphonopeptides and a,a-dialkylated amino acid- 
rich peptides. Compounds in both classes of analogs have been reported to exhibit 
significant bioactivity. The P (El) synthetic approach to phosphonopeptides provided a 
route to phosphonamide dipeptides la  and lc  (Figure 4.1) which were previously 
unattainable by P (V) methods. Additionally, the use of reduced phosphorus 
intermediates allowed preparation of the related thiophosphamides lb  and Id (Figure 
4.1). Ten a,a-dialkylated amino acid (aaAA)-rich peptides, which were designed to be 
amphipathic and 3io-helical, were successfully prepared using solid-phase synthetic 
methods. The helix preference of each peptide in different solvent environments were 
investigated as well as each peptide’s antimicrobial activity and cytotoxicity.
la  X = 0 ,Y  = NH2 
lb  X = S, Y = NH2 
lc  X = O, Y = OCH3 
Id  X = S, Y = OCH3
Figure 4.1 Main phosphonamide and thiophosphonamide synthetic targets
Phosphonamides are generally more difficult to prepare than phosphonate 
diesters. Phosphonamidate’s poor synthetic accessibility has severely limited the use of 
this interesting class of compounds as tools in enzyme chemistry. Chapter 2 described
136
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the conditions we developed, based on a one-pot activation-coupling- 
oxidation/sulfurization procedure, for preparation of sterically hindered phosphonamide 
and thiophosphonamide dipeptides. The commercially available PhsPCfe was used for 
activation of our air-stable precursor, Cbz-protected H-phosphinate amino acid ester 
[Cbz-CyhGly \jr(POH (OpNb)]. From a GC-MS study, it was determined that the 
presence of two equivalents of base (pyridine) during activation of the H-phosphinate 
amino acid ester with PI13PCI2 was essential to preclude ester cleavage. However, as the 
number of equivalents of base increased from two to large excess (e.g., pyridine as 
solvent), the number and amount of side-products increased, as evident by 31P NMR. 
The optimized activation step was generally high-yielding.
During the coupling step, a reactive phosphitylating agent, which we proposed to 
be an oxazaphospholine, formed and competed with the formation of the desired, 
intermediate phosphonamidites. Since the proposed oxazaphospholine was very reactive 
(electrophilic), it was purposely generated before the amine-coupling step. Each amine- 
nucleophile was coupled to the oxazaphospholine, instead of the initial activated P (III) 
species (a phosphonochioridite), to form two coupling, diastereomeric products instead of 
the possible four. This may have indicated a lack of stereoselectivity when amine adds 
directly to the phosphonochioridite.
Oxidation and sulfurization of the intermediate phosphonamidites were easily 
accomplished with t-butylhydroperoxide and elemental sulfur, respectively. Using our 
developed conditions, the previously inaccessible phosphonamide hapten precursor la  
and related derivatives lb-d were prepared. In an alternate procedure, we found that the 
addition of 2 equivalents of an amine-nucleophile with 3.5 equivalents of DEEA to the
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phosphonochioridite followed by sulfiirization/oxidation could also form 1 , but as a 
mixture of four diastereomers instead of two. The former method, incorporating the 
oxazaphospholine, was also applied in the preparation of simpler phosphonamide and 
thiophosphonamide dipeptides and thiophosphonates.
The potential use of the non-urethane amine-protecting groups, Dde and Nbs, 
were also investigated in our phosphonopeptide syntheses. These amine-protecting 
groups were incorporated to lessen the formation of cyclized intermediates or 
oxazaphospholines, which is sometimes undesired in peptide synthesis. The coupling of 
an amine-nucleophiie to a Nbs-protected phosphonochioridite results in the expectant 
diastereomeric mixture of phosphonamidites along with only a small amount of the 
proposed oxazaphospholine. However, with a Dde-protected phosphonochioridite, the 
formation of an oxazaphospholine isn’t observed during amine-coupling, but the overall 
coupling reaction with this type of species doesn’t proceed as well as the reaction with a 
Nbs-protected phosphonochioridite.
Future studies in the area of phosphonopeptide synthesis using reduced 
phosphorus species include the incorporation of non-participating amino protection (via 
solution-or solid-phase), use of milder activation agents, development of analytical 
conditions or techniques for separation of diastereomeric mixtures of phosphonopeptides, 
and solid-supported approaches. The amenability of the P (III) synthetic approach to 
solid-phase methods could be very valuable. In phosphonopeptides prepared by the P 
(IQ) protocol, diversity can be achieved around the phosphorus center as well as by the 
different side-chains of the a-amino acids coupled to them. Therefore, the next logical 
step, for the long-term, would be the adaptation of the solid-phase methodology to the
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simultaneous synthesis (combinatorial chemistry) of several peptides, which could be 
beneficial in the search for therapeutic agents.
Chapter 4 described the synthesis of short, aaAA-rich peptides, the effects of 
different solvent environments on their 3to-/a-helix equilibrium, and the peptides’ in vitro 
antimicrobial activity and cytotoxicity. The peptides were designed to be amphipathic 
and 3io-helical. They were prepared to test the hypothesis that shortened, amphipathic 
310-helical peptides would retain biological activity while becoming increasingly 
selective Cess cytotoxic) in bacterial killing over normal mammalian cells. This was 
based on the trend observed between the length of a peptide and cytotoxicity and helicity 
and bioactivity. The trend was that the shorter the peptide the higher and lower the 
selectivity and cytotoxcity, respectively, and the more helical the peptide the greater the 
activity.
Four homologous series of 9-mer, actAA-rich peptides (and their acetylated 
versions) as well as previously described 10-mer peptide (and its acetylated version) were 
successfully prepared using solid-phase synthetic methods. The 9-mers were comprised 
of 78% aaAAs (6 Aibs and 1 Api) and two lysine or lysine-like residues, and the 10-mers 
were composed of 80% aaAAs (6 Aibs and 2 Api’s) and two lysines. The 9-mers 
differed only in the length of their a-amino acid side-chains. The in situ coupling agent, 
PyAOP, was used in the synthesis. The coupling yields as well as the overall yields of 
the peptides were significantly improved when the dimer, Fmoc-Aib-Aib-OH, was 
employed in the synthesis; however, it was essential that the monomer, Aib, be 
incorporated, along with double coupling, for the first two Aibs in each peptide’s 
sequence.
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The solvent effects on each peptide’s 3 io-/a-helix equilibrium were measured in 
aqueous buffer, 25 mM SDS, and 50-100% aqueous/organic solvent mixtures. 
Significant populations of both a- and 3io-helices were generally observed for the non- 
acetylated 9-mer peptides under all of the solvent conditions tested. Ipidap-9, which was 
comprised of the shortest a-amino acid side-chains, was helical (mainly a-helix) only in 
CH3CN:H2 0  (9:1). The amphipathic, 3io-helical design was observed best, of the non- 
acetylated 9-mers, for Ipiom-9 (R = 0.48) in neutral, aqueous buffer at 25 °C. 
Interestingly, Ipi-10, which is apparently 3io-helical (R = 0.32) at 5 °C in SDS micelles 
and CH3CN-TFE (9:1), is more a-helical at 25 °C under these solvent conditions as well 
as in the other solvent environments it was measured in. This wasn’t a trend observed in 
the other peptides. Further shortening of Ipi-10 to Ipi-9, however, did result in the better 
310-helical stabilization in 25 mM SDS at 25 °C.
A temperature study was also conducted on the 9-mer peptides. A general 
decrease in stability, based on absolute ellipticity values, was observed for the peptides in 
buffer upon heating to 70 °C. However, the thermal transition of each peptide was 
appreciably reversible. Furthermore, during the temperature studies as well as the solvent 
studies no isodichroic point was observed.
The 3io-helical, amphipathic design, based on R values, was observed best for the 
acetylated peptides, specifically AcIpiom-9 and Aclpi-10. AcIpiom-9 folded appreciably 
into a 3io-heIix in 25 mM SDS and CH3CN-TFE (9:1) and Aclpi-10, in 25 mM SDS. 
AcIpidab-9 also adopted the 3io-helical conformation to a substantial extent in CH3CN- 
TFE (9:1). In buffer, all of the acetylated peptides (R=l) folded mainly into an a-helix.
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The antimicrobial activity of our designed peptides was tested against E. coli and 
S. aureus. The shortening of Ipi-10 to the 9-mer peptides resulted in diminished but 
modest activity against E. coli. Of the non-acetylated peptides, Ipiom-9, which had the 
highest percent 3io-helicity in neutral buffer, had the best activity against E. coli. Aclpi- 
9, which had the highest estimated 3io-helicity in 25 mM SDS, was the only acetylated 
peptide of the acetylated-9-mers to exhibit any activity against E. coli. Of all ten of the 
peptides, Aclpi-10, which displayed a R value of 0.38 and 41% 3jo-helicity in SDS 
micelles, had the best activity against E.coli. Practically no activity against S. aureus was 
observed for any of the peptides.
The shortening of Ipi-10 to the 9-mer peptides did not lead to any significant 
cytotoxicity in the concentration range of 10-100 uM. Ipi-9 and Ipidab-9 were only 
slightly toxic at 200 uM. None of the tested acetylated peptides exhibited any significant 
cytotoxicity.
Potential future studies include the introduction of a suitable transition metal or 
salt bridges for possible induction of helical stabilization (preferably 3io-heIix) in the 9- 
mer, aaAA-rich peptides and the determination of the effects (e.g., helix preference and 
stability, bioactivity, etc.) of increasing the length of the side-chains of the 9-mers 
(starting from Ipi-9). The in vitro and in vivo testing of the 9-mers (acetylated and non- 
acetylated) against intracellular pathogens, like Brucella, is also a potential future area of 
investigation.
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